[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 597
1. Zhao XF, Hassan A, Perry A, Ning Y, Stass SA, Dehner LP: C-MYC rearrangements are frequent in aggressive mature B-Cell lymphoma with atypical morphology. Int J Clin Exp Pathol; 2008;1(1):65-74
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-MYC rearrangements are frequent in aggressive mature B-Cell lymphoma with atypical morphology.
  • Diagnosis and classification of aggressive mature B-cell lymphoma with atypical morphology remains a challenge.
  • To identify factors that may contribute to the atypical morphology, we selected eight such cases and evaluated their morphologic, immunophenotypic and cytogenetic features and clinical outcomes.
  • The neoplastic cells showed a diffuse monotonous infiltrating pattern with a spectrum of morphology including:.
  • The lymphoma cells in most cases were positive for CD10 and/or BCL6, and showed BCL2 expression.
  • Clinical follow-up indicated that aggressive mature B-cell lymphoma may benefit from more intensified chemotherapeutic regimens used for BL.
  • Our study suggests that aggressive mature B-cell lymphoma with atypical morphology may be another "grey zone lymphoma" lying in the spectrum between Burkitt lymphoma and diffuse large B-cell lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2002 Jul;15(7):771-6 [12118116.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1148-60 [12946230.001]
  • [Cites] Leukemia. 2007 Mar;21(3):515-23 [17230227.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2495-8 [16760450.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] Blood. 2005 May 15;105(10):3979-86 [15677569.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Diagn Mol Pathol. 2004 Dec;13(4):197-206 [15538109.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Blood. 1998 Feb 1;91(3):984-90 [9446660.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):282-7 [7519050.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6835-9 [3116544.001]
  • [Cites] J Pathol. 2004 Aug;203(4):940-5 [15258997.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):519-28 [15160914.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):510-18 [10653866.001]
  • (PMID = 18784824.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480535
  • [Keywords] NOTNLM ; Aggressive mature B-cell lymphoma / Burkitt lymphoma / C-MYC rearrangement / diffuse large B-cell lymphoma / grey zone lymphoma
  •  go-up   go-down


2. Okudaira T, Nagasaki A, Miyagi T, Taira T, Ohshima K, Takasu N: Intensive chemotherapy for a patient with primary cutaneous diffuse large B-cell lymphoma with Burkitt-like morphology. Intern Med; 2009;48(6):475-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy for a patient with primary cutaneous diffuse large B-cell lymphoma with Burkitt-like morphology.
  • We report a rare case of primary cutaneous diffuse large B-cell lymphoma (DLBCL) with Burkitt-like morphology.
  • Pathological examination showed morphological features resembling Burkitt or Burkitt-like lymphoma (BL/BLL) with high MIB-1 positivity.
  • The present case suggests that short-term, high-intensity chemotherapy used for BL/BLL may be appropriate for primary cutaneous Burkitt-like DLBCL, as well as systemic lymphoma with Burkitt-like morphology.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19293550.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol
  •  go-up   go-down


3. Nomura Y, Karube K, Suzuki R, Ying G, Takeshita M, Hirose S, Nakamura S, Yoshino T, Kikuchi M, Ohshima K: High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients. Cancer Sci; 2008 Feb;99(2):246-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients.
  • The aim of the present study was to estimate optimum chemotherapeutic regimens for high-grade mature B-cell lymphoma cases with Burkitt-like morphology (Burkitt's lymphoma [BL]/Burkitt-like lymphoma [BLL]) patients.
  • We analyzed 72 BL/BLL, including 36 with the c-myc translocation (molecular BL [mBL]), 20 without it (mBL-like), and 16 in whom we were uncertain regarding the existence of the c-myc translocation, and compared them with 182 diffuse large B-cell lymphoma (DLBCL) cases.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Female. Humans. Immunohistochemistry. Immunophenotyping. Japan. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18271922.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Flossbach L, Kestler HA, Gress TM, Möller P, Barth TF: [Current aspects of the pathology and differentiation of extranodal marginal zone B-cell lymphoma, MALT-Type, and gastrointestinal diffuse large B-cell lymphoma]. Z Gastroenterol; 2010 Aug;48(8):833-8
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current aspects of the pathology and differentiation of extranodal marginal zone B-cell lymphoma, MALT-Type, and gastrointestinal diffuse large B-cell lymphoma].
  • The marginal zone B-cell lymphoma, MALT-type (MZBL, MT) is a low-grade B-cell lymphoma which is predominantly localised in the stomach with a typical morphology and cytogenetic pattern.
  • The coexistence of a diffuse large B-cell lymphoma (DLBCL) with an MZBL, MT in the gastrointestinal tract is defined as a composite lymphoma (ComL) and represents a fascinating model of lymphoma progression.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / metabolism. Lymphoma, B-Cell, Marginal Zone / pathology. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20687020.001).
  • [ISSN] 1439-7803
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


5. Stein H, Bob R: Is Hodgkin lymphoma just another B-cell lymphoma? Curr Hematol Malig Rep; 2009 Jul;4(3):125-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is Hodgkin lymphoma just another B-cell lymphoma?
  • For many decades it was regarded as a disease separate from non-Hodgkin lymphoma.
  • However, recent studies have shown that the dysplastic cells of Hodgkin lymphoma (HL) are monoclonal B cells.
  • This finding raised again the question "Is HL just another B-cell lymphoma?
  • " This article reviews the different aspects of HL and B-cell non-Hodgkin lymphoma (B-NHL), concluding that-despite the same cell of origin-fundamental differences exist in morphology, cellular composition, immunophenotype, activation or inhibition of transcription factors, epigenetics, and clinical behavior.
  • [MeSH-major] B-Lymphocytes / pathology. Hodgkin Disease / diagnosis. Lymphoma, B-Cell / diagnosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425425.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Transcription Factors
  • [Number-of-references] 36
  •  go-up   go-down


6. Bernd HW, Ziepert M, Thorns C, Klapper W, Wacker HH, Hummel M, Stein H, Hansmann ML, Ott G, Rosenwald A, Müller-Hermelink HK, Barth TF, Möller P, Cogliatti SB, Pfreundschuh M, Schmitz N, Trümper L, Höller S, Löffler M, Feller AC, German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. Haematologica; 2009 Nov;94(11):1569-80
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials.
  • BACKGROUND: Research on prognostically relevant immunohistochemical markers in diffuse large B-cell lymphomas has mostly been performed on retrospectively collected clinical data.
  • This is also true for immunohistochemical classifiers that are thought to reflect the cell-of-origin subclassification of gene expression studies.
  • In order to obtain deeper insight into the heterogeneous prognosis of diffuse large B-cell lymphomas and to validate a previously published immunohistochemical classifier, we analyzed data from a large set of cases from prospective clinical trials with long-term follow-up.
  • DESIGN AND METHODS: We performed morphological and extensive immunohistochemical analyses in 414 cases of diffuse large B-cell lymphoma from two prospective randomized clinical trials (NHL-B1/B2, Germany).
  • Classification into germinal center and non-germinal center subtypes of B-cell lymphoma was based on the expression pattern of CD10, BCL6, and IRF4.
  • RESULTS: Analyzing 20 different epitopes on tissue microarrays, expression of HLA-DR, presence of CD23(+) follicular dendritic cell meshworks, and monotypic light chain expression emerged as International Prognostic Index-independent markers of superior overall survival.
  • Immunoblastic morphology was found to be related to poor event-free survival.
  • CONCLUSIONS: The previously reported International Prognostic Index-independent prognostic value of stratification into germinal center/non-germinal center B-cell lymphoma using the expression pattern of CD10, BCL6, and IRF4 was not reproducible in our series.
  • [MeSH-major] HLA-DR Antigens / analysis. Lymphoma, Large B-Cell, Diffuse / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Pathol. 1987;1(4):217-25 [3332879.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1988-93 [1913547.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4251-8 [14976040.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] N Engl J Med. 1980 Aug 7;303(6):293-300 [6770268.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] J Immunol. 1982 Oct;129(4):1446-50 [6286767.001]
  • [Cites] Blood. 1982 Nov;60(5):1068-74 [6751435.001]
  • [Cites] Blood. 1984 May;63(5):1209-15 [6370335.001]
  • [Cites] Hematol Oncol. 1984 Jul-Sep;2(3):269-306 [6384008.001]
  • [Cites] Acta Histochem Suppl. 1985;31:269-81 [3927407.001]
  • [Cites] Acta Histochem Suppl. 1985;31:283-94 [3927408.001]
  • [Cites] J Immunol. 1986 Jul 15;137(2):400-7 [2941479.001]
  • [Cites] Int J Cancer. 1987 Jul 15;40(1):32-9 [3298077.001]
  • [Cites] Blood. 1987 Sep;70(3):629-36 [3304458.001]
  • [Cites] Int J Cancer. 1987 Nov 15;40(5):598-603 [3316049.001]
  • [Cites] J Clin Invest. 1988 Jul;82(1):370-2 [3392214.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6387-93 [16155024.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7060-8 [16129841.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4207-13 [16449523.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4135-42 [16943530.001]
  • [Cites] Arch Pathol Lab Med. 2006 Dec;130(12):1819-24 [17149956.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):805-12 [17327602.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):542-6 [17454596.001]
  • [Cites] Ann Oncol. 2007 May;18(5):931-9 [17395602.001]
  • [Cites] Leuk Lymphoma. 2007 May;48(5):892-6 [17487732.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6666-72 [18006767.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3425-33 [18544678.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Hum Pathol. 1992 Aug;23(8):940-7 [1353748.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1996 Jan 1;87(1):265-72 [8547651.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2131-8 [8683246.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2291-7 [9116271.001]
  • [Cites] Blood. 1997 Jul 1;90(1):244-51 [9207459.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1113-20 [15920553.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3904-9 [11051236.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3569-77 [11071656.001]
  • [Cites] Blood. 2001 Aug 15;98(4):945-51 [11493437.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):97-104 [11908742.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Blood. 2003 Jan 1;101(1):78-84 [12393466.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4279-84 [12576316.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Blood. 1991 Feb 15;77(4):809-17 [1704265.001]
  • (PMID = 19880780.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA-DR Antigens
  • [Other-IDs] NLM/ PMC2770968
  •  go-up   go-down


7. Peces R, Vega-Cabrera C, Peces C, Pobes A, Fresno MF: [MALT B cell lymphoma with kidney damage and monoclonal gammopathy: a case study and literature review]. Nefrologia; 2010;30(6):681-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MALT B cell lymphoma with kidney damage and monoclonal gammopathy: a case study and literature review].
  • [Transliterated title] Linfoma de células B tipo MALT con afectación renal y gammapatía monoclonal: presentación de un caso y revisión de la literatura.
  • We report a case of low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) involving the left kidney and simultaneous onset of a monoclonal gammopathy IgM kappa.
  • The demonstration of bone marrow cells of B-lineage expressing the same monoclonal protein as the tumor suggested bone marrow involvement, even in the absence of identical morphology.
  • This case illustrates that the kidney is among the sites that may be involved by MALT B-cell lymphomas in a primary or secondary fashion, and the need for expanded investigation of the possible dissemination.
  • We review the literature on this unusual extranodal lymphoma.
  • [MeSH-major] Immunoglobulin M / blood. Immunoglobulin kappa-Chains / blood. Kidney Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Paraproteinemias / etiology. Paraproteins / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21113219.001).
  • [ISSN] 0211-6995
  • [Journal-full-title] Nefrología : publicación oficial de la Sociedad Española Nefrologia
  • [ISO-abbreviation] Nefrologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulin M; 0 / Immunoglobulin kappa-Chains; 0 / Paraproteins; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, Thorns C, Feller AC, Lenze D, Hummel M, Stein H, Müller-Hermelink HK, Frank M, Hansmann ML, Barth TF, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Loeffler M, Rosenwald A: Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood; 2010 Dec 2;116(23):4916-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
  • The survival of diffuse large B-cell lymphoma patients varies considerably, reflecting the molecular diversity of tumors.
  • Within the cohort of DLBCLs patients treated in the RICOVER-60 trial of the German High-Grade Lymphoma Study Group (DSHNHL), we tested the prognostic impact of IB morphology in 949 patients.
  • IB morphology, however, emerged as a robust, significantly adverse prognostic factor in multivariate analysis, and its diagnosis showed a good reproducibility among expert hematopathologists.
  • We conclude, therefore, that IB morphology in DLBCL is likely to capture some of the adverse molecular alterations that are currently not detectable in a routine diagnostic setting, and that its recognition has significant prognostic power.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gene Expression Profiling. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Germinal Center / pathology. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphoma, Large-Cell, Immunoblastic / classification. Lymphoma, Large-Cell, Immunoblastic / metabolism. Lymphoma, Large-Cell, Immunoblastic / pathology. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Rituximab. Tissue Array Analysis. Treatment Outcome. Vincristine / administration & dosage


9. Knapp FB, Rieh E, Spreer J, Klenzner T, Maier W: [Primary B-cell non-Hodgkin lymphoma of the internal auditory canal: case report and literature review]. HNO; 2008 Jun;56(6):633-7
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary B-cell non-Hodgkin lymphoma of the internal auditory canal: case report and literature review].
  • A primary non-Hodgkin lymphoma (NHL) of the internal auditory canal or the cerebellopontine angle is an absolute rarity, even among the unusual lesions encountered there.
  • However, clinical symptoms or the image morphology cannot confirm the diagnosis of a lymphoma.
  • The course, diagnostics, and therapy of a rare case of primary B-cell NHL of the internal auditory canal are reported here.
  • [MeSH-major] Ear Canal / pathology. Ear Neoplasms / diagnosis. Ear Neoplasms / therapy. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Neurosci. 2005 Sep;12(7):829-32 [16169731.001]
  • [Cites] AJR Am J Roentgenol. 2001 May;176(5):1319-26 [11312202.001]
  • [Cites] Otol Neurotol. 2002 Nov;23(6):975-9 [12438865.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):346-56 [10375091.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1996 Feb;21(1):80-3 [8674229.001]
  • [Cites] Am J Otol. 1997 May;18(3):386-92 [9149836.001]
  • [Cites] Arch Otolaryngol. 1985 Jan;111(1):50-2 [3871326.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3865-70 [16864853.001]
  • [Cites] Surg Neurol. 2004 Jul;62(1):80-5 [15226085.001]
  • [Cites] Laryngorhinootologie. 1997 Oct;76(10):625-8 [9445529.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Jul;262(7):550-4 [15947938.001]
  • [Cites] Otolaryngol Head Neck Surg (1979). 1980 Sep-Oct;88(5):555-9 [6969383.001]
  • [Cites] Surg Neurol. 1998 Nov;50(5):480-5; discussion 485-6 [9842877.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4151-6 [14615443.001]
  • (PMID = 18066510.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 14
  •  go-up   go-down


10. Wang RC, Jan YJ, Wen MC, Wang J, Hsieh PP: Primary appendiceal precursor B lymphoblastic lymphoma with peculiar morphology mimicking diffuse large B cell lymphoma. Pathol Int; 2010 Oct;60(10):690-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary appendiceal precursor B lymphoblastic lymphoma with peculiar morphology mimicking diffuse large B cell lymphoma.
  • Most precursor lymphoblastic lymphoma are T-cell lineage and precursor B lymphoblastic lymphoma constitutes only about 10% of cases according to the WHO Classification of Tumours of Haematologic and Lymphoid Tissues.
  • The most frequent sites of involvement in precursor B lymphoblastic lymphoma are the skin, soft tissue, bone and lymph nodes.
  • We present an unusual case of primary appendiceal precursor B lymphoblastic lymphoma in an 11-year-old boy with peculiar histological morphology mimicking diffuse large B cell lymphoma.
  • The response to conventional treatment regimen for lymphoblastic lymphoma was not good, with early relapse within three months.
  • The special morphologic changes and poor response to chemotherapy may be related to the overexpression of p53.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Pathology International © 2010 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 20846268.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


11. Meziane M, Hesse S, Chetaille B, Bien-Aimée A, Grob JJ, Richard MA: [Cutaneous large B-cell leg-type lymphoma occurring on a leg burn]. Ann Dermatol Venereol; 2009 Nov;136(11):791-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous large B-cell leg-type lymphoma occurring on a leg burn].
  • [Transliterated title] Lymphome B cutané a grandes cellules "de type jambe" sur cicatrice de brûlure.
  • BACKGROUND: Primary cutaneous B-cell lymphomas form a heterogeneous group of lymphoid proliferations found on the skin.
  • We report a case of primary leg-type cutaneous large B-cell lymphoma occurring on the site a previous leg burn.
  • A few rare cases of cutaneous lymphoma forming on burn scars have been described, but these concern primary cutaneous lymphomas of the T-cell phenotype.
  • Histological examination of the skin biopsy revealed the existence in the skin ulcers of atypical large lymphoid cells having an immunoblastic or centroblastic morphology and shown by immunohistochemistry to be of the B-cell phenotype, thereby evoking a diagnosis of large B-cell lymphoma.
  • The lymphoma cells were positive for MUM1/IRF4 and BCL2, and more weakly for BCL6, but negative for CD10.
  • DISCUSSION: This case is novel in that it involves primary large B-cell lymphoma, leg type, occurring on burn scar tissue.
  • Venous insufficiency and lymphatic stasis have already been incriminated in the genesis of this type of lymphoma; the prior injury and resulting immune dysregulation at the burn site may have also contributed to the development of this neoplasia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burns / complications. Lymphoma, B-Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917431.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


12. Coelho Siqueira SA, Ferreira Alves VA, Beitler B, Otta MM, Nascimento Saldiva PH: Contribution of immunohistochemistry to small B-cell lymphoma classification. Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):1-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of immunohistochemistry to small B-cell lymphoma classification.
  • Although the small B-cell lymphomas show major morphologic overlapping, they have been recently shown to be distinct entities with several biologic and clinical differences.
  • Using clinical data and morphologic criteria, 134 cases of small B-cell lymphomas were grouped as those with (1) one strongly suggested diagnosis, (2) differential diagnosis between two types of lymphomas, and (3) small B-cell lymphoma without hints for further subclassification.
  • When all groups were considered, a correct diagnosis could be established for 88.1% of cases; for 6.7% of them the authors remained with two possible diagnosis, and the broad "small B-cell lymphoma" was the only diagnosis for 5.2% of cases.
  • CD10 separated most follicular lymphomas from other small B-cell lymphoid neoplasms.
  • CD23 separated small lymphocytic lymphoma/chronic lymphocytic leukemia.
  • Cyclin D1 separated mantle cell lymphoma.
  • The present study selected CD10, CD23, and cyclin D1 as a minimal panel for the classification of small B-cell lymphomas, yielding a final diagnosis in 88.1% of the cases.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540722.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


13. Camara DA, Stefanoff CG, Pires AR, Soares F, Biasoli I, Zalcberg I, Spector N, Lopes VS, Morais JC: Immunoblastic morphology in diffuse large B-cell lymphoma is associated with a nongerminal center immunophenotypic profile. Leuk Lymphoma; 2007 May;48(5):892-6
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoblastic morphology in diffuse large B-cell lymphoma is associated with a nongerminal center immunophenotypic profile.
  • Diffuse large B cell lymphomas (DLCBL) are a group of lymphomas whose biologic and prognostic diversity has been recently well characterized.
  • There is also morphologic heterogeneity, but the relevance of subclassification remains uncertain.
  • The World Health Organization Classification states that pathologists have the choice to use only the term diffuse large B-cell lymphoma or to use one of the specific morphologic variants.
  • The aim of the present study was to evaluate if there is an association between immunoblastic morphology and the immunophenotypic profile in DLBCL.
  • Cases of immunoblastic lymphoma and cases of centroblastic polymorphic lymphoma with more than 50% immunoblasts were defined as having immunoblastic morphology.
  • Patients with immunoblastic morphology more frequently had a non-GCB phenotype (94% vs 6%).
  • This finding suggests that the morphological subclassification of DLBCL does have biological meaning, in line with recent evidence indicating that the immunoblastic morphology should not be overlooked in lymphoma classification.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Immunophenotyping / methods. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / chemistry. Cell Transformation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Phenotype. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487732.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


14. Zattra E, Pigozzi B, Bordignon M, Marino F, Chiarion-Sileni V, Alaibac M: Anetoderma in cutaneous marginal-zone B-cell lymphoma. Clin Exp Dermatol; 2009 Dec;34(8):e945-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anetoderma in cutaneous marginal-zone B-cell lymphoma.
  • Histological examination found an infiltrate composed of neoplastic cells with lymphoplasmocytoid morphology.
  • A diagnosis of cutaneous marginal-zone B-cell lymphoma was made.
  • [MeSH-major] Anetoderma / metabolism. B-Lymphocytes / metabolism. Lymphoma, B-Cell, Marginal Zone / metabolism. Skin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778307.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A: Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology; 2007 Mar;50(4):498-508
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics.
  • AIMS: To identify distinguishing histological, immunophenotypic and molecular genetic features between angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma (PTL).
  • METHODS: Nodal T-cell lymphomas examined (n =137), included AITL (n = 89), PTL (n = 22), anaplastic large cell lymphoma (n = 16) and 'AITL/PTL indeterminate' (n = 10) with overlapping features between AITL and PTL, showing morphology typical of AITL but lacking follicular dendritic cell expansion.
  • Immunohistochemistry for CD3, CD20, CD21 and CD10, in situ hybridization for Epstein-Barr virus encoded RNA (EBER) and polymerase chain reaction for T-cell and B-cell clonality analysis were performed.
  • RESULTS: Of the AITLs, 74/89 showed typical morphology, whereas 15/89 showed hyperplastic follicles.
  • Detection of T-cell clonality was significantly higher in AITL (90%) compared with PTLu (59%).
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis
  • [MeSH-minor] Antigens, CD20 / metabolism. Antigens, CD3 / metabolism. B-Lymphocytes / pathology. Clone Cells. Diagnosis, Differential. Gene Rearrangement. Herpesvirus 4, Human / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Immunophenotyping. Neprilysin / metabolism. Polymerase Chain Reaction. RNA, Viral / analysis. Receptors, Antigen, T-Cell, gamma-delta / genetics. Receptors, Complement 3d / metabolism. Sensitivity and Specificity. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448026.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Immunoglobulin Heavy Chains; 0 / RNA, Viral; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


16. Pfistershammer K, Petzelbauer P, Stingl G, Mastan P, Chott A, Jäger U, Skrabs C, Geusau A: Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma with an 'angiocentric' histological morphology. Clin Exp Dermatol; 2010 Jan;35(1):59-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma with an 'angiocentric' histological morphology.
  • Thus, this patient was classified as having a rare form of an EBV-negative primary cutaneous T-cell-rich B-cell lymphoma in association with methotrexate treatment.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Lymphoma, Large B-Cell, Diffuse / chemically induced. Lymphoma, Large B-Cell, Diffuse / pathology. Methotrexate / adverse effects. Skin Neoplasms / chemically induced. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486063.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


17. Weisberger J, Gorczyca W, Kinney MC: CD56-positive large B-cell lymphoma. Appl Immunohistochem Mol Morphol; 2006 Dec;14(4):369-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56-positive large B-cell lymphoma.
  • CD56 (NCAM), a neural adhesion molecule, is normally expressed on natural killer cells and subsets of T cells and is commonly seen on hematolymphoid neoplasms such as plasma cell myeloma and acute myelogenous leukemia.
  • It is uncommon in B-cell lymphoma.
  • From 2001 to 2003 a cohort of 20 cases of CD56 B-cell lymphomas was identified by flow cytometry (<0.5% of all B-cell lymphomas studied) during a 2-year period.
  • These CD56 B-cell lymphomas may represent a new subset of large B-cell lymphoma.
  • The relationship of cells with this antigenic profile to normal B-cell differentiation is explored.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122631.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


18. Shimoyama Y, Sakakibara A, Kawai K, Nagasaka T, Nakamura S: Molecular diagnosis of malignant lymphoma: mantle cell lymphoma, anaplastic large cell lymphoma, and marginal zone B-cell lymphoma of malt. Nagoya J Med Sci; 2006 Jan;68(1-2):1-8
Genetic Alliance. consumer health - Mantle cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnosis of malignant lymphoma: mantle cell lymphoma, anaplastic large cell lymphoma, and marginal zone B-cell lymphoma of malt.
  • Malignant lymphoma is a heterogeneous category embracing three major types of lymphoid neoplasms: B cell neoplasms, T and NK cell neoplasms, and Hodgkin lymphoma.
  • Within each type, distinct disease entities are defined based on a combination of morphology, immunophenotype, genetic features and clinical syndromes, the emphasis on which represents a new paradigm in the lymphoma classification of the World Health Organization (WHO).
  • These lymphoma entities often have distinctive cytogenetic abnormalities, usually involving translocations that place a potential cellular oncogene under the influence of the immunoglobulin in some low-grade B-cell lymphomas.
  • Both pathologists and oncologists are now concerned with better understanding each disease entity and its spectrum of morphology, genetic events, and clinical behaviors.
  • Over the last decade, significant progress has been made in the molecular characterizations of mantle cell lymphoma, anaplastic large cell lymphoma, and marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), which have not only provided insights into the pathogenesis of lymphomas, but also valuable data that could lead to therapies based on their clinical behavior.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Mantle-Cell / diagnosis. Molecular Diagnostic Techniques

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579170.001).
  • [ISSN] 0027-7622
  • [Journal-full-title] Nagoya journal of medical science
  • [ISO-abbreviation] Nagoya J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 136601-57-5 / Cyclin D1; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 23
  •  go-up   go-down


19. Nava VE, Cohen P, Bishop M, Fowler D, Jaffe ES, Ozdemirli M: Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell lymphoma. Am J Surg Pathol; 2007 Mar;31(3):476-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell lymphoma.
  • A rare case of enteropathy-type T-cell lymphoma (ETL) developed in a 47-year-old Chinese male 6 years after the diagnosis of diffuse large B-cell lymphoma (DLBCL) in the small intestine.
  • Clinical work-up revealed thickening of the small intestinal wall, and biopsies demonstrated ETL based on morphology, immunohistochemistry, and polymerase chain reaction analysis.
  • The patient responded to chemotherapy, received allogeneic peripheral blood stem cell transplantation from an HLA-matched sibling donor, and remains in remission.
  • Possible associations between the 2 types of lymphoma are discussed.
  • [MeSH-major] Intestinal Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Celiac Disease / complications. Celiac Disease / diagnosis. Chemotherapy, Adjuvant. Humans. Immunohistochemistry. Male. Neoplasm Staging. Peripheral Blood Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325491.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Kim JY, Kim YC, Lee ES: Precursor B-cell lymphoblastic lymphoma involving the skin. J Cutan Pathol; 2006 Sep;33(9):649-53
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell lymphoblastic lymphoma involving the skin.
  • Precursor B-cell lymphoblastic lymphoma (B-LBL) is a rare neoplasm composed of immature lymphocytes that demonstrate lymphoblastic morphology and express precursor and B-cell marker.
  • Immunohistochemical study showed that the lymphoid cells of infiltrate showed precursor B-cell type.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Skin Neoplasms / pathology. Stem Cells / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2006.
  • (PMID = 16965342.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


21. Tsuji K, Suzuki D, Naito Y, Sato Y, Yoshino T, Iwatsuki K: Primary cutaneous marginal zone B-cell lymphoma. Eur J Dermatol; 2005 Nov-Dec;15(6):480-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous marginal zone B-cell lymphoma.
  • We report a Japanese case of primary cutaneous marginal zone B-cell lymphoma (PCMZL).
  • With the combined morphology,the immunophenotype, and molecular analysis, we diagnosed this lesion as PCMZL.
  • The chromosomal aberrations in MALT lymphoma such as t(11;18)(q21;q21), t(14;18)(q32;q21) and t(3;14)(p14.1;q32) were not reported in any of the Japanese cases.
  • Although two patients developed metastasis on the skin after radiation therapy, none died of lymphoma.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280304.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 14
  •  go-up   go-down


22. Huang Q, Wilczynski SP, Chang KL, Weiss LM: Composite recurrent hodgkin lymphoma and diffuse large B-cell lymphoma: one clone, two faces. Am J Clin Pathol; 2006 Aug;126(2):222-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite recurrent hodgkin lymphoma and diffuse large B-cell lymphoma: one clone, two faces.
  • We describe a composite lymphoma with recurrent Hodgkin lymphoma and diffuse large B-cell lymphoma components manifesting as a single, perforated small intestinal tumor in a 56-year-old man with a history of classical Hodgkin lymphoma and recent relapse in the bone marrow.
  • The adjacent component displayed sheets of relatively uniform, large lymphoid cells with typical morphologic features of diffuse large cell lymphoma.
  • The tumor cells showed uniform expression of tested B-cell antigens, absence of CD30 or CD15, and complete absence of EBV-encoded RNA.
  • Such distinctly different morphology, immunophenotype, and EBV status in different components within a clonally related single tumor mass is striking.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Recurrence, Local. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891197.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Viral
  •  go-up   go-down


23. Traverse-Glehen A, Pittaluga S, Gaulard P, Sorbara L, Alonso MA, Raffeld M, Jaffe ES: Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol; 2005 Nov;29(11):1411-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.
  • In recent years, overlap in biologic and morphologic features has been identified between classic Hodgkin lymphoma (cHL) and B-cell non-Hodgkin lymphoma.
  • We undertook a study of "mediastinal gray zone lymphomas" (MGZL), with features transitional between cHL nodular sclerosis (NS) and primary mediastinal large B-cell lymphoma (MLBCL) to better understand the morphologic and immunophenotypic spectrum of such cases.
  • We also studied 6 cases of composite or synchronous lymphoma with two distinct components at the same time (cHL-NS and MLBCL) and 9 sequential cases with MLBCL and cHL-NS at different times.
  • Immunohistochemical studies focused on markers known to discriminate between cHL and MLBCL, including B-cell transcription factors.
  • Of the gray zone cases, 11 had morphology reminiscent of cHL-NS, but with unusual features, including a large number of mononuclear variants, diminished inflammatory background, absence of classic Hodgkin phenotype, and strong CD20 expression (11 of 11).
  • Ten cases had morphology of MLBCL, but with admixed Hodgkin/Reed-Sternberg and lacunar cells, absent (3 of 10) or weak (7 of 10) CD20 expression, and positivity for CD15 in 7 cases.
  • B-cell transcription factor expression in the gray zone cases more closely resembled MLBCL than cHL with expression of Pax5, Oct2, and BOB.1 in all but 1 case studied (14 of 15).
  • Two cases of sequential lymphoma showed rearrangements of the IgH gene of identical size: one in which MLBCL was the first diagnosis and one in which MLBCL was diagnosed at relapse, indicating clonal identity for the two components of cHL and MLBCL.
  • Further support for a relationship between MLBCL and cHL-NS is provided by composite and metachronous lymphomas in the same patient, as well as the existence of MGZL with transitional morphology and phenotype.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Mediastinal Neoplasms / pathology

  • Genetic Alliance. consumer health - Gray zone lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224207.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


24. Liu A, Sugisaki Y, Hosone M, Namimatsu S, Maeda S, Naito Z, Ghazizadeh M: CD30-positive diffuse large B-cell lymphoma with microvillous features: so-called microvillous lymphoma. J Clin Pathol; 2009 Sep;62(9):840-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30-positive diffuse large B-cell lymphoma with microvillous features: so-called microvillous lymphoma.
  • A case of CD30-positive microvillous lymphoma (MVL) in an 87-year-old man who was encountered generalised lymphadenopathy is presented.
  • Histopathologically, the tumour showed a morphological mimic of anaplastic large cell lymphoma (ALCL) with sinusoidal growth pattern.
  • In conclusion, CD30-positive MVLs are indistinguishable from ALCLs that have ultrastructural microvillous projections by morphology alone.
  • The results of a panel of three markers (CD10(-), Bcl-6(+) and MUM1(+)) suggested that the present case of CD30-positive MVLs has an activated non-germinal centre B-cell origin.
  • [MeSH-major] Antigens, CD30 / analysis. Lymphoma, Large B-Cell, Diffuse / ultrastructure
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Lymphoma, Large-Cell, Anaplastic / diagnosis. Male. Microscopy, Electron. Microvilli / ultrastructure

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126565.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Isaacson PG, Du MQ: Gastrointestinal lymphoma: where morphology meets molecular biology. J Pathol; 2005 Jan;205(2):255-74
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal lymphoma: where morphology meets molecular biology.
  • Primary gastrointestinal lymphomas are best exemplified by mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach and enteropathy-type T-cell lymphoma (ETL).
  • Here, the histopathology and recent advances in phenotypic and molecular characterization of gastric MALT lymphoma and ETL and their applications in diagnosis and clinical management are reviewed.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Chromosome Aberrations. Diagnosis, Differential. Humans. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15643667.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 130
  •  go-up   go-down


26. Matutes E: Adult T-cell leukaemia/lymphoma. J Clin Pathol; 2007 Dec;60(12):1373-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukaemia/lymphoma.
  • Adult T-cell leukaemia/lymphoma (ATLL) is a mature T-cell neoplasm of post-thymic lymphocytes aetiologically linked to the human T-cell lymphotropic virus, HTLV-I, and with a distinct geographical distribution.
  • According to the disease manifestations, various forms which differ in clinical course and prognosis have been recognised: acute, chronic, smouldering and lymphoma.
  • The latter comprise: lymphocyte morphology, immunophenotype, histology of the tissues affected in the pure lymphoma forms and serology or DNA analysis for HTLV-I.
  • The differential diagnosis of ATLL includes other mature T-cell neoplasms such as T-cell prolymphocytic leukaemia (T-PLL), Sézary syndrome (SS), peripheral T-cell lymphomas and occasionally healthy carriers of the virus or Hodgkin disease.
  • The clinical course is aggressive with a median survival of less than 12 months in the acute and lymphoma forms.
  • Consolidation with high dose therapy and autologous or allogeneic stem-cell transplantation should be considered in young patients.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Oct 1;56(7):1688-90 [2992744.001]
  • [Cites] Int J Cancer. 1985 Jan 15;35(1):65-72 [2578441.001]
  • [Cites] Lancet. 1987 Jul 11;2(8550):94-5 [2885585.001]
  • [Cites] Blood. 1987 Nov;70(5):1554-64 [2889485.001]
  • [Cites] Blood. 1988 Apr;71(4):1027-32 [2895676.001]
  • [Cites] Lancet. 1990 Oct 20;336(8721):987-90 [1977015.001]
  • [Cites] Lancet. 1991 Jan 12;337(8733):76-7 [1670727.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1622-8 [2001551.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):213-6 [7904671.001]
  • [Cites] Leukemia. 1994 Nov;8(11):1834-7 [7967729.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Leukemia. 1995 Apr;9(4):594-7 [7723390.001]
  • [Cites] Leukemia. 1995 Apr;9(4):598-604 [7723391.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):615-9 [7734362.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1744-8 [7760890.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] Leuk Lymphoma. 1995 May;17(5-6):459-64 [7549838.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):703-11 [9674744.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Blood. 2005 May 15;105(10):4143-5 [15665110.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):511-5 [16098064.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3380-2 [16076875.001]
  • [Cites] Leuk Res. 2006 Jan;30(1):103-5 [15979704.001]
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):637-40 [10609805.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):41-4 [16247419.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1392-6 [18042695.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):779-84 [11380470.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):304-9 [12542491.001]
  • [Cites] Am J Hematol. 2004 Jun;76(2):187-9 [15164389.001]
  • [Cites] Leuk Res. 1985;9(11):1353-9 [2867255.001]
  • (PMID = 18042693.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 42
  • [Other-IDs] NLM/ PMC2095573
  •  go-up   go-down


27. Rodríguez-Pinilla SM, Atienza L, Murillo C, Pérez-Rodríguez A, Montes-Moreno S, Roncador G, Pérez-Seoane C, Domínguez P, Camacho FI, Piris MA: Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol; 2008 Dec;32(12):1787-99
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with follicular T-cell markers.
  • INTRODUCTION: Peripheral T-cell lymphomas (PTCLs) in western countries are uncommon tumors with unfavorable prognosis.
  • They may be subclassified as anaplastic large-cell lymphomas (ALCLs), angioimmunoblastic-T-cell lymphomas (AITLs), or unspecified peripheral T-cell lymphomas (PTCLs-U).
  • The aim of this study was to establish whether other PTCL subgroups also express TFH cell markers.
  • PD-1-positive cases, which did not fulfill all the criteria for AITL, were further evaluated in whole-tissue sections for another 12 immunohistochemical markers, including the TFH cell markers CXCL13, CD10, and BCL6.
  • Clonal Ig and T-cell receptor rearrangements and Epstein-Barr virus-encoded RNA expression were also evaluated.
  • Morphologic, clinical, and follow-up data were reviewed.
  • All cases expressed at least 2 TFH cell markers.
  • Of the remainder, 1 was considered to be early AITL, 1 was diagnosed as ALCL-anaplastic lymphoma kinase-negative, and 4 of the other 6 PTCLs-U had morphology consistent with lymphoepithelioid (Lennert's) lymphoma.
  • CONCLUSIONS: TFH cell markers, especially PD-1, were expressed in a subset of PTCLs not classified as AITL, although most of them shared some morphologic features with AITL.
  • This suggests that the spectrum of AITL may be wider than previously thought, possibly including cases of lymphoepithelioid (Lennert's) lymphoma.
  • [MeSH-major] Antigens, CD / biosynthesis. Apoptosis Regulatory Proteins / biosynthesis. Biomarkers / analysis. Lymphoma, T-Cell, Peripheral / classification. Lymphoma, T-Cell, Peripheral / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemokine CXCL13 / biosynthesis. Female. Gene Rearrangement, T-Lymphocyte. Humans. Immunohistochemistry. In Situ Hybridization. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Neprilysin / biosynthesis. Programmed Cell Death 1 Receptor. Proto-Oncogene Proteins / biosynthesis. Repressor Proteins / biosynthesis. T-Lymphocytes, Helper-Inducer / metabolism. T-Lymphocytes, Helper-Inducer / pathology. Tissue Array Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779728.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / BCOR protein, human; 0 / Biomarkers; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


28. Li S: Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity. Int J Clin Exp Pathol; 2009;2(6):508-18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity.
  • Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK(+) LBCL) represents a distinct subtype of mature B-cell neoplasms in the most recent WHO classification of hematolymphoid neoplasms.
  • It has a characteristic immunoblastic/plasmablastic morphology, a distinct immunophenotypic profile and recurrent cytogenetic/molecular genetic abnormalities, and has been reported in both the adult and pediatric populations.
  • With the advent of new ALK inhibitors for possible targeted therapy clinical trials, it is important to recognize this new entity, particularly in the pediatric population because the prognosis is worse than the more common ALK+ anaplastic large cell lymphoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2009 Feb;174(2):361-70 [19131589.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] Hum Pathol. 2009 Jan;40(1):75-82 [18755494.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):930-5 [18724359.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):975-8 [18923525.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):971-4 [18923524.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):967-70 [18923523.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):108-13 [18220322.001]
  • [Cites] Med Res Rev. 2008 May;28(3):372-412 [17694547.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):13-7 [18166835.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22 [18089725.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):940-5 [17509395.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4408-17 [17483355.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):770-8 [17439836.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Histopathology. 2007 Jan;50(2):278-82 [17222259.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5 [17185414.001]
  • [Cites] Tumori. 2006 Sep-Oct;92(5):449-51 [17168442.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3275-9 [17094440.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(16):6209-22 [16880530.001]
  • [Cites] Gene Expr Patterns. 2006 Jun;6(5):448-61 [16458083.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):649-53 [15852431.001]
  • [Cites] Rinsho Ketsueki. 2005 Jul;46(7):501-6 [16440742.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):390-1 [16086416.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1839-40 [16107887.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3191-6 [16101126.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1128-34 [15902287.001]
  • [Cites] Pol J Pathol. 2005;56(1):37-45 [15921012.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1609-14 [15577680.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2776-80 [10383129.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1954-60 [7655022.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1285-8 [15492998.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):828-32 [12920229.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1919-27 [12424201.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Aug;34(4):354-62 [12112524.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1364-71 [11684952.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):411-5 [11485898.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):569-76 [11406658.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):9526-31 [11121404.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1711-21 [10793082.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7750-61 [14586401.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7 [19088198.001]
  • (PMID = 19636398.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2713458
  • [Keywords] NOTNLM ; ALK / Anaplastic lymphoma kinase / CLTC/ALK / diffuse large B-cell lymphoma / t(2;17)
  •  go-up   go-down


29. Stacy NI, Nabity MB, Hackendahl N, Buote M, Ward J, Ginn PE, Vernau W, Clapp WL, Harvey JW: B-cell lymphoma with Mott cell differentiation in two young adult dogs. Vet Clin Pathol; 2009 Mar;38(1):113-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphoma with Mott cell differentiation in two young adult dogs.
  • Cytologic and histologic examination of intestinal and liver masses and mesenteric lymph nodes revealed 2 distinct lymphoid cell populations: lymphoblasts and atypical Mott cells.
  • Antigen receptor gene rearrangement analysis of lymph node and intestinal masses indicated a clonal B-cell population.
  • Based on cell morphology, tissue involvement, and evidence for clonal B-cell proliferation, we diagnosed neoplasms involving Mott cells.
  • To the authors' knowledge, this is the second report of Mott cell tumors or, more appropriately, B-cell lymphoma with Mott cell differentiation, in dogs.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19171017.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Sant M, Allemani C, De Angelis R, Carbone A, de Sanjosè S, Gianni AM, Giraldo P, Marchesi F, Marcos-Gragera R, Martos-Jiménez C, Maynadié M, Raphael M, Berrino F, EUROCARE-3 Working Group: Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer; 2008 Mar;44(4):579-87
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States.
  • We explored the influence of morphology on geographic differences in 5-year survival for non-Hodgkin lymphoma (NHL) diagnosed in 1990-1994 and followed for 5years: 16,955 cases from 27 EUROCARE-3 cancer registries, and 22,713 cases from 9 US SEER registries.
  • Excess risk of death was significantly above reference (diffuse B lymphoma) for Burkitt's and NOS lymphoma; not different for lymphoblastic and other T-cell; significantly below reference (in the order of decreasing relative excess risk) for NHL NOS, mantle cell/centrocytic, lymphoplasmacytic, follicular, small lymphocytic/chronic lymphocytic leukaemia, other specified NHL and cutaneous morphologies.
  • Interpretation of marked variation in survival with morphology is complicated by classification inconsistencies.
  • The completeness and standardisation of cancer registry morphology data needs to be improved.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Registries / standards

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18242077.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Oberaigner W; Storm HH; Aareleid T; Hédelin G; Tron I; Le Gall E; Launoy G; Macé-Lesec'h J; Faivre J; Chaplain G; Carli PM; Danzon A; Tretarre B; Colonna M; Lacour B; Raverdy N; Berger C; Freycon F; Grosclaude P; Estêve J; Kaatsch P; Ziegler H; Hölzel D; Fritschle GS; Tryggvadottir L; Berrino F; Allemani C; Balli P; Ciccolallo L; Crosignani P; Gatta G; Micheli A; Sant M; Ferretti S; Conti E; Ramazzotti V; Vercelli M; Quaglia A; Pannelli F; Federico M; Artioloi ME; Ponze De Leon M; Benatti P; De Lisi V; Servente L; Zanetti R; Patriarca S; Magnani C; Pastore G; Gafà L; Tumino R; Falcini F; Budroni M; Paci E; Crocetti E; Zambon P; Guzzinati S; Capocaccia R; Carrani E; De Angelis R; Roazzi P; Santaquilani M; Tavilla A; Valente F; Verdecchia A; Dalmas M; Langmark F; Andersen A; Rachtan J; Bielska-Lasota M; Wronkowski Z; Plesko I; Obsitníková A; Pompe-Kirn V; Izarzugaza I; Martinez-Garcia C; Garau I; Navarro C; Chirlaque MD; Ardanaz E; Moreno C; Galceran J; Torrella A; Peris-Bonet R; Barlow L; Möller T; Jundt G; Lutz JM; Usel M; Coebergh JW; van der Does-van den Berg A; Visser O; Godward S; Forman D; Quinn MJ; Roche M; Edwards S; Stiller C; Verne J; Møller H; Bell J; Botha JL; Lawrence G; Black R; Steward JA; Conti E
  •  go-up   go-down


31. Sriganeshan V, Blom TR, Weissmann DJ: A unique case of mantle cell lymphoma with an aberrant CD5-/CD10+ immunophenotype and typical morphology. Arch Pathol Lab Med; 2008 Aug;132(8):1346-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique case of mantle cell lymphoma with an aberrant CD5-/CD10+ immunophenotype and typical morphology.
  • Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma with a poor prognosis that may be confused with less aggressive diseases, such as small lymphocytic lymphoma and follicular lymphoma.
  • In many cases immunophenotyping, particularly analysis of reactivity for CD5 and CD10, is an important adjunct to morphology that usually distinguishes MCL from follicular lymphoma; the former is CD5(+)/CD10(-), whereas follicular lymphoma is the reverse.
  • We report a case of MCL, initially diagnosed as follicular lymphoma, that at presentation expressed neither CD5 nor CD10.
  • An MCL with this immunophenotype and classical morphology has not been previously reported.
  • [MeSH-major] Antigens, CD5 / analysis. Head and Neck Neoplasms / immunology. Head and Neck Neoplasms / pathology. Immunophenotyping. Lymphoma, Mantle-Cell / immunology. Lymphoma, Mantle-Cell / pathology. Neprilysin / analysis

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684040.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 136601-57-5 / Cyclin D1; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 15
  •  go-up   go-down


32. Tageja N, Mohammad M, Bentley G, Bishop C: Adult T-Cell Leukemia/Lymphoma with CLL-Like Morphology-A Case Report. Case Rep Med; 2010;2010:729790

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-Cell Leukemia/Lymphoma with CLL-Like Morphology-A Case Report.
  • Adult T-cell Leukemia/Lymphoma (ATL) is rarely seen in the U.S. and Europe, usually limited to African Americans from the southeastern U.S. and immigrants from HTLV-1 endemic areas.
  • Reaching an accurate and timely diagnosis of ATL in such nonendemic areas can be challenging, owing to limited exposure, diverse manifestations, and varying cell morphology.
  • We present a case of chronic adult T-cell leukemia (ATL) with Chronic Lymphocytic Leukemia- (CLL-) like morphology that remained untreated for ten years and then developed treatment refractory acute ATL crisis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1994 Feb;86(2):383-5 [8199030.001]
  • [Cites] Br J Haematol. 1999 May;105(2):369-75 [10233406.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1373-7 [18042693.001]
  • [Cites] Leuk Lymphoma. 1993 Dec;12(1-2):123-30 [8161929.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J Clin Pathol. 1989 Jun;42(6):567-84 [2738163.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):185-96 [18081707.001]
  • (PMID = 20368783.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2846349
  •  go-up   go-down


33. McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, Hoering A, Kurtin PJ: Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol; 2005 Dec;29(12):1652-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.
  • Adult, de novo B-cell lymphomas meeting the WHO morphologic criteria for atypical Burkitt/Burkitt-like lymphoma cause diagnostic difficulty for pathologists because the genetic and clinical characteristics of this group of lymphomas have not been clearly defined.
  • Thirty-one such lymphomas, designated as Burkitt-like lymphomas (BLL), were selected based on morphologic features and evaluated for immunophenotype, MYC and BCL2 status, and clinical features.
  • Nine childhood Burkitt lymphomas (BL) and 87 adult, de novo diffuse large B-cell lymphomas (DLBL) were similarly evaluated for comparison.
  • The BL group demonstrated uniform characteristics: all had Burkitt lymphoma morphology, an identical immunophenotype (positive for CD20, CD10, bcl-6, CD43, and p53; negative for CD138, CD23, bcl-2), high MIB-1 positivity, IGH/MYC translocation, no IGH/BCL2 translocation, and all patients were alive at the last follow-up.
  • Burkitt-like morphology alone correlated with decreased survival.
  • MIB-1 positivity did not correlate with morphology, MYC abnormalities, or survival.
  • We propose that adult B-cell lymphomas with BLL morphology are a phenotypically and genetically heterogeneous group of aggressive lymphomas, biologically distinct from childhood BL.
  • Until biologically accurate subgroups within this morphologically defined group are identified, it is appears that both recognition of BLL morphology and direct evaluation for the presence of MYC fusion to immunoglobulin genes are important for identification of adult patients with poorer prognosis than those with DLBL.
  • [MeSH-major] Burkitt Lymphoma / genetics. Genotype. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Phenotype

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327438.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


34. Zhang D, Denley RC, Filippa DA, Teruya-Feldstein J: ALK-positive diffuse large B-cell lymphoma with the t(2;17)(p23;q23). Appl Immunohistochem Mol Morphol; 2009 Mar;17(2):172-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma with the t(2;17)(p23;q23).
  • Diffuse large B-cell lymphoma (DLBCL) with plasmablastic features associated with t(2;17)(p23;q23) and characteristic granular cytoplasmic anaplastic lymphoma kinase-1 (ALK1) protein expression is a rare lymphoma subtype.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19521280.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


35. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol; 2010 Mar;34(3):327-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
  • B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as "double-hit" lymphomas (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, and a spectrum of pathologic features overlapping with Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B-lymphoblastic lymphoma/leukemia (B-LBL).
  • The clinical and pathologic spectrum of this rare entity, including comparison to other high-grade B-cell neoplasms, has not been well defined.
  • Six patients had a history of grade 1 to 2 follicular lymphoma; review of the prior biopsy specimens in 2 of 5 cases revealed blastoid morphology.
  • Twelve DHL cases (60%) were classified as B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL, 7 cases (35%) as DLBCL, not otherwise specified, and 1 case as B-LBL.
  • DHL is a high-grade B-cell neoplasm with a poor prognosis, resistance to multiagent chemotherapy, and clinical and pathologic features distinct from other high-grade B-cell neoplasms.
  • Familiarity with the morphologic and immunophenotypic spectrum of DHL is important in directing testing to detect concurrent IGH-BCL2 and MYC rearrangements when a karyotype is unavailable.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Regulation, Neoplastic. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Genes, Immunoglobulin Heavy Chain. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-myc / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):525-34 [10757399.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1960-6 [11069032.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):52-4 [11120335.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51 [11343778.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):610-3 [12708908.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):474-9 [15239399.001]
  • [Cites] Blood. 1983 Nov;62(5):1142-6 [6605167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70 [6334305.001]
  • [Cites] Am J Clin Pathol. 1986 May;85(5):636-40 [3486584.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] N Engl J Med. 1988 May 26;318(21):1373-8 [3285208.001]
  • [Cites] Oncogene. 1988 May;2(5):431-5 [3131717.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1454-9 [2509518.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Jul;2(2):147-58 [2278969.001]
  • [Cites] Oncogene. 1991 Jan;6(1):145-8 [1992441.001]
  • [Cites] Leukemia. 1991 Jan;5(1):83-7 [1999960.001]
  • [Cites] Leukemia. 1991 Jun;5(6):473-8 [1711639.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Ann Hematol. 1991 Nov;63(5):282-7 [1958753.001]
  • [Cites] Ann Hematol. 1992 Feb;64(2):101-4 [1554791.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leukemia. 1994 Apr;8(4):560-3 [8152251.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):87-94 [8019967.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):55-61 [9541684.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):414-23 [15852472.001]
  • [Cites] Hum Pathol. 2005 May;36(5):571-5 [15948125.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1490-6 [16224216.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2313-23 [16193090.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Nov;171(1):52-6 [17074591.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1061-4 [17182663.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Am J Clin Pathol. 2008 Jan;129(1):157-66 [18089500.001]
  • [Cites] Curr Protoc Hum Genet. 2007 Jan;Chapter 8:Unit 8.8 [18428417.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1593-607 [18753947.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):716-25 [19120369.001]
  • [Cites] Leukemia. 2009 Feb;23(2):225-34 [18923440.001]
  • [Cites] Leukemia. 2009 Apr;23(4):777-83 [19151788.001]
  • [Cites] Haematologica. 2009 Jul;94(7):935-43 [19535347.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • (PMID = 20118770.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R37 CA076404; United States / NIGMS NIH HHS / GM / T32 GM074897; United States / NIGMS NIH HHS / GM / T32 GM074897-07
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ NIHMS305320; NLM/ PMC3152212
  •  go-up   go-down


36. Bilić E, Femenić R, Konja J, Simat M, Dubravcić K, Batinić D, Ries S, Rajić L: CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience. Coll Antropol; 2010 Mar;34(1):171-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience.
  • Lymphomas represent the third most common group of cancers in childhood and adolescence, mature B non Hodgkin's lymphoma (B-NHL) accounting for up to 60% of newly diagnosed patients.
  • The diagnosis of specific entities of B-NHL is based on well-defined morphologic analysis, immunophenotyping, cytogenetics and molecular genetics, which determine the optimal treatment strategy.
  • Based on morphology and immunophenotype of malignant cells, seven children with B-NHL in our institution were eligible for treatment with modified B-NHL-Berlin-Frankfurt-Münster (BFM)-95-based protocol with rituximab administered on day -5.
  • Major adverse effects observed during treatment were prolonged B-cell depletion and myelosuppression.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology


37. Haycocks NG, Zhao XF: Large B-cell lymphoma with an unusual infiltrating pattern: report of two cases. Int J Clin Exp Pathol; 2010;3(8):815-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large B-cell lymphoma with an unusual infiltrating pattern: report of two cases.
  • Large B-cell lymphoma presents with the most varied infiltrating patterns and morphologies.
  • Here we report two cases of unusual large B-cell lymphoma in two old female patients.
  • 2) large B-cells with an immunoblastic morphology;.
  • 3) large B-cell infiltration associated with vascular proliferation;.
  • To our knowledge, these are the first reported cases of large B-cell lymphomas with a paranodular infiltrating pattern, immunoblastic morphology, and associated vascular proliferation.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):223-8 [10757332.001]
  • [Cites] J Clin Pathol. 1990 May;43(5):429-32 [2370312.001]
  • [Cites] Arch Pathol Lab Med. 2010 Mar;134(3):449-56 [20196672.001]
  • [Cites] Diagn Mol Pathol. 1992 Sep;1(3):173-9 [1342963.001]
  • [Cites] Mod Pathol. 1998 Mar;11(3):239-46 [9521469.001]
  • [Cites] Histopathology. 2008 May;52(6):731-7 [18397280.001]
  • [Cites] Cytometry. 1993 Oct;14(7):702-15 [8243200.001]
  • (PMID = 21151397.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2993234
  • [Keywords] NOTNLM ; DLBCL / Paranodular / angioproliferative / immunoblastic
  •  go-up   go-down


38. Wu JM, Georgy MF, Burroughs FH, Weir EG, Rosenthal DL, Ali SZ: Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone? Diagn Cytopathol; 2009 Nov;37(11):820-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone?
  • The differentiation of benign versus malignant hematologic processes on cerebrospinal fluid (CSF) is difficult given the significant morphologic overlap and frequently scant specimen.
  • The spectrum of disease ranged from acute myeloid leukemia, mantle cell lymphoma, chronic lymphocytic lymphoma, Burkitt lymphoma, large cell lymphoma, T cell lymphoma, and non-Hodgkin lymphoma.
  • Of the malignant cases, there was a higher proportion of correct diagnosis based on morphology in the acute malignancies (67%) versus the chronic malignancies (47%).
  • The diagnosis of malignancy based on morphology alone is difficult in CSF.
  • [MeSH-major] Flow Cytometry. Leukemia / cerebrospinal fluid. Leukemia / diagnosis. Lymphoma / cerebrospinal fluid. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526571.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Liao YL, Chang ST, Kuo SY, Lin SH, Chen CK, Chang KM, Chuang SS: Angioimmunoblastic T-cell lymphoma of cytotoxic T-cell phenotype containing a large B-cell proliferation with an undersized B-cell clonal product. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):185-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma of cytotoxic T-cell phenotype containing a large B-cell proliferation with an undersized B-cell clonal product.
  • Angioimmunoblastic T-cell lymphoma is a nodal peripheral T-cell lymphoma considered to be derived from CD4 follicular helper T cells.
  • We presented the case of a 60-year-old male patient with angioimmunoblastic T-cell lymphoma, in which the neoplastic T cells expressed CD8, bcl-6, and programmed death-1.
  • The results of T-cell receptor gene rearrangement study using the Biomed-2 protocols showed clonal rearrangement with amplicons falling within the expected size ranges.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19956067.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD8; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / BCL6 protein, human; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


40. Chang CC, Zhou X, Taylor JJ, Huang WT, Ren X, Monzon F, Feng Y, Rao PH, Lu XY, Fabio F, Hilsenbeck S, Creighton CJ, Jaffe ES, Lau CC: Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol; 2009 Nov 12;2:47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma.
  • BACKGROUND: Plasmablastic lymphoma (PL) is a subtype of diffuse large B-cell lymphoma (DLBCL).
  • Studies have suggested that tumors with PL morphology represent a group of neoplasms with clinopathologic characteristics corresponding to different entities including extramedullary plasmablastic tumors associated with plasma cell myeloma (PCM).
  • There were some segmental gains and some segmental loss that occurred in PL but not in the other types of lymphoma suggesting that these foci may contain genes responsible for the differentiation of this lymphoma.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2004 Aug 7;4:45 [15298715.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):299-303 [14981516.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Sep 1;16(1):1-9 [9377118.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2477-85 [16317097.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):313-25 [16616336.001]
  • [Cites] Neoplasia. 2008 Jan;10(1):89-98 [18231642.001]
  • [Cites] Mod Pathol. 2008 May;21(5):599-608 [18246049.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):281-91 [18398573.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] FEBS Lett. 2000 Jan 28;466(2-3):367-71 [10682862.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):e15 [11842121.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] J Hepatol. 2003 Mar;38(3):298-306 [12586295.001]
  • [Cites] Clin Lymphoma. 2003 Sep;4(2):86-92 [14556679.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • (PMID = 19909553.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NLM NIH HHS / LM / R01 LM010185; United States / NIDCR NIH HHS / DE / DE017086
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2789747
  •  go-up   go-down


41. Zhao FX: Nodular lymphocyte-predominant hodgkin lymphoma or T-cell/histiocyte rich large B-cell lymphoma: the problem in "grey zone" lymphomas. Int J Clin Exp Pathol; 2008;1(3):300-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte-predominant hodgkin lymphoma or T-cell/histiocyte rich large B-cell lymphoma: the problem in "grey zone" lymphomas.
  • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare indolent B-cell lymphoma.
  • However, its morphology can resemble T-cell/histiocyte rich large B-cell lymphoma (T/HRBCL), a subtype of more aggressive diffuse large B-cell lymphoma.
  • In this report, a 59-year-old man with nodal NLPHL and concomitant T/HRBCL in the bone marrow is presented, the current progress in our understanding of these two closely related B-cell lymphomas reviewed and the problems in the diagnosis and differentiation of NLPHL and T/HRBCL discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1742-50 [7602364.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2312-20 [7662978.001]
  • [Cites] Histopathology. 1991 Sep;19(3):211-20 [1655614.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):599-606 [3041849.001]
  • [Cites] Am J Surg Pathol. 1984 Apr;8(4):253-61 [6369997.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1551-7 [15370206.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):229-36 [14687617.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3753-8 [12881319.001]
  • [Cites] Blood. 2003 Jan 15;101(2):706-10 [12393409.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1807-14 [11696441.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:266-72 [17124071.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):805-14 [17050078.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):585-92 [16699312.001]
  • [Cites] J Pathol. 2006 Feb;208(3):423-30 [16353293.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):42-4 [16007867.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):31-5 [9541680.001]
  • [Cites] N Engl J Med. 1997 Aug 14;337(7):459-65 [9250848.001]
  • [Cites] N Engl J Med. 1997 Aug 14;337(7):453-8 [9250847.001]
  • [Cites] Blood. 1996 Jul 15;88(2):657-66 [8695813.001]
  • [Cites] APMIS. 1995 Sep;103(9):655-62 [7488387.001]
  • [Cites] Mod Pathol. 1995 Jun;8(5):544-7 [7675775.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):526-30 [8172327.001]
  • (PMID = 18784812.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480562
  • [Keywords] NOTNLM ; Nodular lymphocyte-predominant Hodgkin lymphoma / T-cell/histiocyte rich large B-cell lymphoma / “grey zone” lymphoma
  •  go-up   go-down


42. Hunt KE, Hall B, Reichard KK: Translocations involving MUM1 are rare in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):109-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocations involving MUM1 are rare in diffuse large B-cell lymphoma.
  • Diffuse large B-cell lymphoma (DLBCL) comprises a diverse group of neoplasms that have recently been subdivided by gene expression profiling and immunohistochemical studies into at least 2 subgroups [germinal center (GC) type and non-GC type].
  • We hypothesized that MUM1 may be dysregulated/up-regulated in these tumors by a chromosomal translocation, as is seen in many cases of plasma cell myeloma [where MUM1 is juxtaposed with the immunoglobulin heavy chain gene (IgH)].

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18815567.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4
  •  go-up   go-down


43. Frank MC, Bono E, Sun T: An unusual case of peripheral T-cell lymphoma with CD56 positivity and angiocentric, angiodestructive morphology arising in the ileum. Arch Pathol Lab Med; 2005 Apr;129(4):527-30
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of peripheral T-cell lymphoma with CD56 positivity and angiocentric, angiodestructive morphology arising in the ileum.
  • Natural killer cell and cytotoxic T-cell lymphomas are frequently difficult to distinguish because they share many common features, and yet it is important to make an accurate diagnosis because their prognoses differ.
  • We report an unusual case of a white man with a CD56-positive T-cell lymphoma in the ileum.
  • Immunohistochemical staining showed positive reactions to CD3, CD8, CD43, CD45RO, CD56, and T-cell intracellular antigen-1, but negative reactions to CD4, CD5, CD20, CD23, and CD57.
  • The T-cell receptor gamma chain gene was rearranged.
  • According to the World Health Organization classification, the absence of EBV excludes the diagnosis of extranodal natural killer/T-cell lymphoma, nasal type.
  • However, the association of EBV with this lymphoma in white patients is not clear.
  • Therefore, absence of EBV alone does not necessarily exclude nasal-type natural killer/T-cell lymphoma, particularly because the histologic pattern in this case is highly characteristic of this tumor.
  • [MeSH-major] Ileal Neoplasms / pathology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Aged. Antigens, CD56 / metabolism. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Immunohistochemistry. Male. Neovascularization, Pathologic

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794680.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


44. Laskov R, Berger N, Scharff MD, Horwitz MS: Tumor necrosis factor-alpha and CD40L modulate cell surface morphology and induce aggregation in Ramos Burkitt's lymphoma cells. Leuk Lymphoma; 2006 Mar;47(3):507-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor-alpha and CD40L modulate cell surface morphology and induce aggregation in Ramos Burkitt's lymphoma cells.
  • Interaction of CD40L and its cognate receptor is an essential component of B-lymphocyte signaling, affecting various aspects of B-cell differentiation pathways and immunoglobulin gene expression.
  • However, much less is known about the biological consequences of B-cell signaling through tumor necrosis factor (TNF)-alpha and its cognate receptors TNF-R1 and 2.
  • We used Ramos Burkitt's lymphoma cell line as a model system to study the direct effects of these cytokines on B cells.
  • Treatment of Ramos cells with either TNF-alpha or CD40L, but not with interleukin (IL)- 4, interferon (IFN)-gamma and transforming growth factor (TGF)-beta, resulted in enhanced cell aggregation and enhancement of adherence to glass cover-slips.
  • Scanning electron microscopy showed that Ramos cells have a polarized cell surface morphology and exhibit at least 3 cell surface morphological domains: microvilli, filopodia and ruffled membranes.
  • The cells adhered to the glass matrix through multiple filopodia/podopodia-like cell processes and demonstrated distinct ruffled-like membrane projections on their opposite pole.
  • [MeSH-major] Burkitt Lymphoma / immunology. Burkitt Lymphoma / pathology. CD40 Ligand / pharmacology. Cell Aggregation / drug effects. Cell Membrane / drug effects. Tumor Necrosis Factor-alpha / pharmacology
  • [MeSH-minor] Antigens, CD95. Cell Adhesion / drug effects. Cell Line, Tumor. Humans. Intercellular Adhesion Molecule-1 / drug effects. Intercellular Adhesion Molecule-1 / immunology. Receptors, Tumor Necrosis Factor / drug effects. Receptors, Tumor Necrosis Factor / immunology. Receptors, Tumor Necrosis Factor, Type I / biosynthesis. Receptors, Tumor Necrosis Factor, Type II / biosynthesis. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523591.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / 1PO1 DK52956; United States / NIAID NIH HHS / AI / AI43937; United States / NCI NIH HHS / CA / CA72649
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FAS protein, human; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1; 147205-72-9 / CD40 Ligand
  •  go-up   go-down


45. Hedvat CV, Teruya-Feldstein J, Puig P, Capodieci P, Dudas M, Pica N, Qin J, Cordon-Cardo C, Di Como CJ: Expression of p63 in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol; 2005 Sep;13(3):237-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p63 in diffuse large B-cell lymphoma.
  • The p63 gene, a homolog of the tumor suppressor gene TP53, maps to chromosome 3q27-28, a region frequently displaying genomic amplification in squamous cell carcinomas. p63 is expressed in a variety of epithelial tissues and has been reported to be critical for the normal development of stratified epithelia, including skin epidermis.
  • In a previous study, the authors reported the expression of p63 in occasional cells in the germinal center of lymph nodes and also observed p63 expression in B-cell lymphomas, among other tumor types surveyed in that analysis.
  • The present study was conducted to further analyze the potential clinical significance of identifying p63 expression, assessing a larger cohort of well-characterized patients with diffuse large B-cell lymphoma (DLBCL) (n = 172 cases) and a panel of established lymphoma cell lines. p63 expression at the microanatomic detail was examined by immunohistochemistry using a monoclonal antibody (clone 4A4), while distinction of p63 isoforms was analyzed by Western blotting and reverse transcription-polymerase chain reaction using isoform-specific primers.
  • Examination of the different p63 isoforms revealed that the DeltaNp63 species was expressed by only one cell line, while the other p63 isoforms were found in most cell lines analyzed.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082248.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-47179; United States / NCI NIH HHS / CA / CA-87497; United States / NIDDK NIH HHS / DK / DK-47650; United States / NHLBI NIH HHS / HL / HL-04478
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / Protein Isoforms; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


46. De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, Praet M, De Wolf-Peeters C: Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol; 2005 Oct 1;23(28):7060-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.
  • PURPOSE: The reliability of immunohistochemistry for subdividing diffuse large B-cell lymphomas (DLBCL) into germinal center B-cell-like (GCB) and non-GCB prognostic subgroups is debated.
  • Furthermore, we investigated whether both subgroups could comprise clinicopathologic entities recognized by their morphology and characterized by a distinct phenotype, specific genetic abnormalities, and clinical characteristics.
  • In contrast, immunoblastic morphology was associated with a non-GCB profile and was a significant predictor of unfavorable DFS.
  • Nevertheless, it allowed the additional characterization of two lymphoma subgroups previously recognized in the Working Formulation.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129841.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


47. Wang J, Sun NC, Chen YY, Weiss LM: T-cell/histiocyte-rich large B-cell lymphoma displays a heterogeneity similar to diffuse large B-cell lymphoma: a clinicopathologic, immunohistochemical, and molecular study of 30 cases. Appl Immunohistochem Mol Morphol; 2005 Jun;13(2):109-15
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell/histiocyte-rich large B-cell lymphoma displays a heterogeneity similar to diffuse large B-cell lymphoma: a clinicopathologic, immunohistochemical, and molecular study of 30 cases.
  • T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), a proliferating peripheral B-cell neoplasm, is a morphologic variant of diffuse large B-cell lymphoma (DLBCL), which may be confused with Hodgkin's lymphoma, non-Hodgkin's lymphoma, and reactive lymphadenopathies.
  • These data indicate that similar to DLBCL, the cell origin of neoplastic cells in THRLBCL is composed of a heterogeneous group of proliferating peripheral B cells, with only some cases originating from germinal center B cells and others derived from heterogeneous origins.
  • Lack of Bcl-2 gene rearrangements seems to argue against a possible progression from preexisting follicular lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894921.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


48. Tierens AM, Holte H, Warsame A, Ikonomou IM, Wang J, Chan WC, Delabie J: Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type. Haematologica; 2010 Aug;95(8):1334-41
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type.
  • BACKGROUND: Multiparameter flow cytometry allows the detection of minor monoclonal B-cell populations.
  • Using this technique combined with morphology, we were struck by the presence of minor populations of small monoclonal B cells in bone marrows of patients with diffuse large B-cell lymphoma in routine diagnostic samples and performed a systematic retrospective study.
  • DESIGN AND METHODS: Bone marrows of 165 patients with primary diffuse large B-cell lymphoma without histological evidence of concurrent non-Hodgkin's lymphoma were studied by routine microscopy of trephines and smears, immunohistochemistry and multiparameter flow cytometry.
  • RESULTS: Diffuse large B-cell lymphoma infiltration in marrows was documented in 11 of 165 patients.
  • Of interest, only 3 of 119 patients with diffuse large B-cell lymphoma not otherwise specified, the largest subtype, showed marrow infiltration.
  • By contrast, flow cytometry revealed a minor monoclonal B-cell population in 24 of 165 patients, none of whom showed diffuse large B-cell lymphoma infiltration by morphology.
  • Moreover, 11 of 39 (28.2%) of patients with diffuse large B-cell lymphoma not otherwise specified of ABC subtype and only 3 of 80 (3.7%) with the GCB subtype showed these monoclonal small B cells (P=0.0002).
  • In addition 4 of 8 (50%), 4 of 15 (26.7%) and 2 of 3 (66.7%) patients with primary testicular, primary central nervous system and leg-type diffuse large B-cell lymphoma, respectively, showed monoclonal small B cells.
  • CONCLUSIONS: Bone marrow infiltration with diffuse large B-cell lymphoma in patients with diffuse large B-cell lymphoma not otherwise specified is rare at diagnosis.
  • By contrast, a high number of diffuse large B-cell lymphoma not otherwise specified of the ABC subtype but not of GCB subtype is associated with monoclonal small B cells in the marrow.
  • Whether these monoclonal small B cells are precursors of diffuse large B-cell lymphoma of the ABC type or arise in a common background that favors clonal B-cell expansion remains to be demonstrated.
  • [MeSH-major] B-Lymphocytes / pathology. Bone Marrow Cells / pathology. Germinal Center / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2337-42 [14630808.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):236-42 [1988571.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Am J Clin Pathol. 1994 Mar;101(3):305-11 [8135186.001]
  • [Cites] Leukemia. 1996 May;10(5):877-95 [8656686.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):272-8 [10102612.001]
  • [Cites] Blood. 2005 May 1;105(9):3671-8 [15308563.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):325-32 [16042682.001]
  • [Cites] Blood. 2006 Jan 1;107(1):190-6 [16150948.001]
  • [Cites] J Pathol. 2006 Oct;210(2):163-71 [16823896.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):575-83 [18687638.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] Blood. 2009 Jul 2;114(1):33-7 [19420353.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3889-96 [10572105.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3569-77 [11071656.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Blood. 2002 Jul 15;100(2):635-9 [12091358.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1460-9 [12145686.001]
  • [Cites] Lab Invest. 2003 Jan;83(1):107-14 [12533691.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Jul;54(1):10-8 [12827663.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Haematologica. 2003 Dec;88(12):1358-65 [14687988.001]
  • [Cites] Am J Clin Pathol. 1990 Jul;94(1):59-66 [2360564.001]
  • (PMID = 20145271.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunoglobulin Heavy Chains
  • [Other-IDs] NLM/ PMC2913082
  •  go-up   go-down


49. Haas HS, Pfragner R, Siegl V, Ingolic E, Heintz E, Schauenstein K: Glutamate receptor-mediated effects on growth and morphology of human histiocytic lymphoma cells. Int J Oncol; 2005 Sep;27(3):867-74
Hazardous Substances Data Bank. Glutamine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutamate receptor-mediated effects on growth and morphology of human histiocytic lymphoma cells.
  • We report here that glutamate, as well as glutamate receptor reactive drugs, differentially modulate growth and morphology of human histiocytic lymphoma-derived U937 cells.
  • In contrast, in cultures devoid of glutamate, glutamine and serum, the agonists significantly increased cell proliferation whereas the antagonist CNQX showed no effect.
  • These data point to a significant role of peripheral glutamate receptors in tumor cell proliferation.
  • [MeSH-major] Cell Proliferation / drug effects. Glutamic Acid / pharmacology. Receptors, Glutamate / physiology
  • [MeSH-minor] 6-Cyano-7-nitroquinoxaline-2,3-dione / pharmacology. Cell Shape / drug effects. Culture Media, Serum-Free / pharmacology. Excitatory Amino Acid Agonists / pharmacology. Excitatory Amino Acid Antagonists / pharmacology. Glutamine / pharmacology. Humans. Kainic Acid / pharmacology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / ultrastructure. Microscopy, Electron. Time Factors. U937 Cells. alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16077940.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free; 0 / Excitatory Amino Acid Agonists; 0 / Excitatory Amino Acid Antagonists; 0 / Receptors, Glutamate; 0RH81L854J / Glutamine; 3KX376GY7L / Glutamic Acid; 6OTE87SCCW / 6-Cyano-7-nitroquinoxaline-2,3-dione; 77521-29-0 / alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; SIV03811UC / Kainic Acid
  •  go-up   go-down


50. Liu YH, Zhuang HG, Lin HL, Wu QL, Luo DL, Li L, Luo XL: [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2006 Aug;28(8):594-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
  • OBJECTIVE: To study the differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and T-cell/histiocyte-rich B-cell lymphoma (TCRBCL).
  • METHODS: 15 cases of NLPHL and 16 cases of TCRBCL were studied on both morphology and immunophenotype according to the WHO classification of lymphoid neoplasms.
  • One case showed a combination of nodules of NLPHL, diffuse areas of TCRBCL and a sheet of large cells of diffuse large B-cell lymphoma (DLBCL) within the same lymph node biopsy specimen.
  • CONCLUSION: There are some morphologic and immunophenotypic resemblance between NLPHL and TCRBCL.
  • [MeSH-major] Hodgkin Disease / pathology. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243292.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD57; 0 / Poly(A)-Binding Proteins; 0 / TIA1 protein, human
  •  go-up   go-down


51. Smock KJ, Yaish HM, Cairo MS, Lones MA, Willmore-Payne C, Perkins SL: Mantle cell lymphoma presenting with unusual morphology in an adolescent female: a case report and review of the literature. Pediatr Dev Pathol; 2007 Sep-Oct;10(5):403-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma presenting with unusual morphology in an adolescent female: a case report and review of the literature.
  • We report the case of an 18-year-old female initially diagnosed with CD5-negative diffuse large B-cell lymphoma in an inguinal lymph node in 1999 who subsequently relapsed with classic-morphology mantle cell lymphoma with involvement of the bone marrow, gastrointestinal tract, and spleen in 2004.
  • Both the 1999 and 2004 lesions were retrospectively positive for Cyclin D1 by immunohistochemistry and positive for t(11:14)(q13;q32) by fluorescence in situ hybridization, and both lesions had identical B-cell receptor gene rearrangements by polymerase chain reaction.
  • This case of a CD5-negative large cell or pleomorphic blastoid variant of mantle cell lymphoma arising in an 18-year-old represents a very early incidence for this type of lymphoma, which is usually not seen in younger patients.
  • [MeSH-major] Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / metabolism. Lymphoma, Mantle-Cell / pathology. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols. Cyclin D1 / biosynthesis. Diagnosis, Differential. Female. Flow Cytometry. Gene Rearrangement, B-Lymphocyte. Humans. In Situ Hybridization, Fluorescence. Lymphoma, Large B-Cell, Diffuse / pathology. Translocation, Genetic

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929987.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1
  •  go-up   go-down


52. Gibson SE, Hsi ED: Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol; 2009 May;40(5):653-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype.
  • Epstein-Barr virus-positive B-cell lymphoproliferative disorders similar to those seen in posttransplantation patients have recently been described in immunocompetent, elderly Asian individuals.
  • The clinicopathologic features of 6 Epstein-Barr virus-positive B-cell lymphomas of the elderly from 5 patients 60 years and older were reviewed.
  • The remaining specimens resembled conventional diffuse large B-cell lymphoma.
  • Most tumor cells were Epstein-Barr virus-positive by in situ hybridization and had a nongerminal center B-cell immunophenotype.
  • In addition, 90 cases of diffuse large B-cell lymphoma in patients 60 years and older were screened for Epstein-Barr virus and were negative.
  • Epstein-Barr virus-positive B-cell lymphomas of the elderly occur uncommonly at a United States tertiary medical center.
  • Pathologic features that may aid in identification and trigger Epstein-Barr virus testing include a polymorphic infiltrate, plasmacytic morphology, Reed-Sternberg-like cells, angioinvasion, necrosis, and a nongerminal center B-cell immunophenotype.
  • Further investigation is needed to determine if Epstein-Barr virus status plays an independent role in the prognosis of diffuse large B-cell lymphoma in non-Asian countries, which would also impact the need to screen all diffuse large B-cell lymphoma in older patients for Epstein-Barr virus.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / pathology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology
  • [MeSH-minor] Aged. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Herpesvirus 4, Human. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Polymerase Chain Reaction. Tissue Array Analysis. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144386.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


53. Xie X, Sundram U, Natkunam Y, Kohler S, Hoppe RT, Kim YH, Cook JR, Hammel J, Swerdlow SH, Guitart J, Smith MD, Bosler D, Listinsky C, Lossos IS, Hsi ED: Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma. Mod Pathol; 2008 Jun;21(6):653-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma.
  • The classification of primary cutaneous large B-cell lymphoma (PCLBCL) is based on standard morphology, immunohistochemistry, and clinical presentation.
  • There are two major subtypes in the current WHO-EORTC classification: follicle center lymphoma and diffuse large B-cell lymphoma, leg-type (DLBCL-LT).
  • The goals of this study were to examine a series of DLBCLs to determine (1) whether the immunohistochemical paradigm of germinal center B-cell and non-germinal center B-cell types of systemic DLBCL could be applied to PCLBCL;.
  • (2) whether application of the newly described germinal center B-cell marker, human germinal center-associated lymphoma (HGAL) also discriminates between these types as a further support for germinal center B-cell origin for primary cutaneous center lymphoma; and (3) whether any of these biologic markers were of prognostic significance.
  • HGAL and BCL6 expression and germinal center B-cell phenotype were associated with primary cutaneous follicular center lymphoma.
  • Both HGAL and BCL6 were associated with the germinal center B-cell phenotype.
  • The correlation of HGAL expression with the germinal center B-cell phenotype demonstrates the role of this marker in the classification of cutaneous large B-cell lymphomas.
  • Characterizing PCLBCLs with markers of B-cell maturation stage is a useful framework for studying, classifying, and clinically stratifying these lymphomas.
  • [MeSH-major] Germinal Center / pathology. Lymphoma, Follicular / classification. Lymphoma, Large B-Cell, Diffuse / classification. Neoplasm Proteins / biosynthesis. Neprilysin / biosynthesis. Skin Neoplasms / classification

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264083.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / GCET2 protein, human; 0 / Interferon Regulatory Factors; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


54. Morley AM, Verity DH, Meligonis G, Rose GE: Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit. Orbit; 2009;28(6):425-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
  • OBJECTIVES: To describe two cases of orbital plasmablastic lymphoma (PBL), a recently defined aggressive large-cell lymphoma with a plasmacytic immunophenotype, typically occurring in the oral cavity of HIV+ patients.
  • To compare their presentation, management, immunohistochemistry and prognosis with orbital diffuse large B-cell lymphoma (DLBCL).
  • Both tumours were negative for B-cell markers (CD20, CD79a), showed a plasmacytic immunophenotype (positive for CD 138, Vs38c), and displayed a Ki67 index of 100%.
  • Only 7 (50%) had sinus involvement and 3 (21%) had prior systemic lymphoma.
  • All were positive for B-cell markers, with a Ki67 index of 55%-80%.
  • It must be considered in the differential of orbital large-cell lymphoid tumours showing plasmablastic morphology or immunophenotype.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Orbital Neoplasms / pathology. Plasma Cells / pathology


55. Teruya-Feldstein J, Gopalan A, Moskowitz CH: CD5 negative, Cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen. Appl Immunohistochem Mol Morphol; 2009 May;17(3):255-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD5 negative, Cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen.
  • We present a case of diffuse large B-cell lymphoma CD5 negative, Cyclin D1 positive presenting as ruptured spleen in a 63-year-old man requiring emergent splenectomy.
  • This case raises the differential diagnoses of pleomorphic mantle cell lymphoma and other aggressive lymphomas with pleomorphic, anaplastic, and Reed-Sternberg-like cells.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838919.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


56. Chuang SS, Liu H, Huang Y, Chio CC, Lin LC: Primary cerebral diffuse large B-cell lymphoma relapsed solely in the skin with the same clonal origin. Appl Immunohistochem Mol Morphol; 2009 Jan;17(1):77-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cerebral diffuse large B-cell lymphoma relapsed solely in the skin with the same clonal origin.
  • Diffuse large B-cell lymphoma is the most common type of primary central nervous system (CNS) lymphoma(PCNSL) with poor prognosis.
  • The lymphoma cells of all 3 specimens were of the same histology and immunophenotype with expression of CD20, IgM, bcl-2, bcl-6, and MUM1 but not CD3, CD10, CD30, IgD, cyclin D1,or cutaneous lymphocyte-associated antigen.
  • The brain and skin tumors demonstrated the same clonal origin by B-cell clonality study followed by cloning and sequencing.


57. Baiyee D, Warnke R, Natkunam Y: Lack of utility of CD20 immunohistochemistry in staging bone marrow biopsies for diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol; 2009 Mar;17(2):93-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of utility of CD20 immunohistochemistry in staging bone marrow biopsies for diffuse large B-cell lymphoma.
  • The utility of CD20 immunohistochemistry in the evaluation of staging bone marrow biopsies of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients has not been extensively studied.
  • We used 113 routinely processed bone marrow biopsies to study the extent and pattern of involvement by lymphoma and CD20 staining.
  • Twelve (10.6%) of 113 cases had involvement by morphology, and 5 (41.7%) of these showed histologic discordance between the primary site and the bone marrow.
  • All cases with morphologic evidence of bone marrow involvement showed staining for CD20.
  • One case (0.9%) showed a small benign lymphoid aggregate by immunohistochemistry that was not evident by morphology.
  • Our results demonstrate that CD20 staining did not detect any examples of bone marrow involvement by DLBCL that were not evident by morphology.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2000 Nov;53(11):835-40 [11127265.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1278-82 [17475910.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):636-43 [11939740.001]
  • [Cites] J Clin Pathol. 1984 Mar;37(3):233-54 [6699189.001]
  • [Cites] Am J Surg Pathol. 1989 Feb;13(2):97-106 [2464955.001]
  • [Cites] Eur J Haematol. 1989 May;42(5):445-53 [2471652.001]
  • [Cites] Mod Pathol. 1989 Nov;2(6):618-29 [2587569.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1163-72 [1694234.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):745-50 [1401199.001]
  • [Cites] Am J Clin Pathol. 1994 Mar;101(3):305-11 [8135186.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1336-42 [7751877.001]
  • [Cites] J Clin Pathol. 1999 Apr;52(4):294-300 [10474523.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):920-37 [16231177.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1549-57 [16327427.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):18-23 [16540725.001]
  • [Cites] Eur J Haematol. 2006 Jun;76(6):473-80 [16529599.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):881-3 [11564080.001]
  • (PMID = 19521275.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA034233-22A29002; United States / NCI NIH HHS / CA / P01 CA034233-22A29002; United States / NCI NIH HHS / CA / P01CA34322
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20
  • [Other-IDs] NLM/ NIHMS77742; NLM/ PMC2696064
  •  go-up   go-down


58. Yamauchi A, Ikeda J, Nakamichi I, Kohara M, Fukuhara S, Hino M, Kanakura Y, Ogawa H, Sugiyama H, Kanamaru A, Aozasa K, Osaka Lymphoma Study Group: Diffuse large B-cell lymphoma showing an interfollicular pattern of proliferation: a study of the Osaka Lymphoma Study Group. Histopathology; 2008 May;52(6):731-7
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma showing an interfollicular pattern of proliferation: a study of the Osaka Lymphoma Study Group.
  • AIMS: Diffuse large B-cell lymphoma (DLBCL) usually proliferates effacing lymph follicles.
  • The aim was to analyse clinicopathological findings in DLBCL showing an interfollicular pattern of proliferation to determine whether this type of lymphoma is a distinct entity of DLBCL.
  • METHODS AND RESULTS: Clinicopathological findings in 12 cases of DLBCL showing an interfollicular pattern of proliferation [interfollicular group (IF)] were examined and compared with those in 30 cases of DLBCL with ordinary morphology [control group (CG)].
  • Immunohistochemically, the majority (11 of 12) of IF cases showed a non-germinal centre B-cell phenotype and the frequency was higher than that in CG (P = 0.021).
  • CONCLUSION: Diffuse large B-cell lymphoma with an interfollicular pattern of proliferation shows distinct clinical and pathological findings from ordinary DLBCL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Cell Proliferation. Female. Germinal Center / cytology. Humans. Immunohistochemistry. Japan. L-Lactate Dehydrogenase / metabolism. Male. Middle Aged. Phenotype. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18397280.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


59. Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST: High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia; 2005 May;19(5):851-5
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.
  • Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with two distinct lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD)/MCD-associated plasmablastic lymphoma.
  • Interestingly, all KSHV-positive cases belonged to a distinctive subgroup of 26 diffuse large B-cell lymphomas characterized by the expression of CD138 (syndecan-1) and plasmablastic/immunoblastic morphology.
  • [MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / virology. Herpesviridae Infections / virology. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Lymphoma, Large B-Cell, Diffuse / virology. Sarcoma, Kaposi / virology


60. Carulli G, Orciuolo E, Cannizzo E, Bianchi G, Giuntini S, Ottaviano V, Galimberti S, Marini A, Buda G, Ghimenti M, Petrini M: Combination of morphology, flow cytometry and PCR assay to detect bone marrow infiltration in B-cell non-Hodgkin's lymphomas. Clin Ter; 2010;161(3):253-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of morphology, flow cytometry and PCR assay to detect bone marrow infiltration in B-cell non-Hodgkin's lymphomas.
  • AIMS: Morphology on bone marrow biopsy (BMB) samples has historically been the primary method used to detect bone marrow (BM) infiltration in B-cell non-Hodgkin's lymphoma (NHL), while fl ow cytometry (FC) and PCR assays have been generally used as ancillary methods.
  • Morphology on histologic specimens was used to assess infiltration pattern and immunohistochemistry, FC to analyze immunophenotype, PCR to identify IgH rearrangement, BCL-1/JH and BCL-2/JH translocation.
  • RESULTS: Morphology, FC and PCR assays agreed in 142 cases (73.5%) with more concordance at initial diagnosis than during postchemotherapy follow-up.
  • PCR was the single best-performing test, while combination of morphology and PCR yielded a higher sensitivity than individual methods and was similar to PCR + FC.
  • CONCLUSION: Given the initial importance of histological information evident by morphology, our data suggest that combination of morphology and PCR should be considered the gold standard for evaluation of BM infiltration at diagnosis, while combination of PCR + FC should be employed during post-treatment follow-up.
  • [MeSH-major] Bone Marrow / pathology. Bone Neoplasms / pathology. Flow Cytometry. Lymphoma, B-Cell / pathology. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20589357.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


61. Goy A, Stewart J, Barkoh BA, Remache YK, Katz R, Sneige N, Gilles F: The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma. Cancer; 2006 Feb 25;108(1):10-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma.
  • Lymphoma of germinal center cell (GC) origin generally is an indolent malignancy that transforms progressively into a more aggressive disease.
  • According to the World Health Organization classification, lymphomas of follicular center cell origin are classified as either large B-cell lymphoma (LBCL) or follicular lymphoma (FL).
  • The diagnoses were confirmed by 2 pathologists and were classified into 2 groups (10 LBCL samples and 14 FL samples) by using conventional morphology and immunophenotyping.
  • Gene expression profiling results were analyzed first by principal-component analysis (PCA) by using a list of 146 probe sets that represented 62 genes that are characteristic of an activated B-cell (ABC) signature or a GC signature.
  • The analysis identified 5 LBCL samples with an ABC cell signature.
  • These samples were characterized morphologically by a mixed cell pattern with relatively fewer large, noncleaved lymphocytes and more small, cleaved lymphocytes.
  • The results support the feasibility of FNA-based transcription profiles in patients with FL or LBCL, which, in combination with morphology and immunophenotyping, can help in the subtyping of these entities.
  • [MeSH-major] Biopsy, Fine-Needle. Gene Expression Profiling. Lymphoma, B-Cell / genetics. Lymphoma, Follicular / genetics. Lymphoma, Large B-Cell, Diffuse / genetics

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • [CommentIn] Cancer. 2007 Jun 25;111(3):200-1; author reply 201-2 [17520702.001]
  • (PMID = 16329118.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Flatland B, Fry MM, Newman SJ, Moore PF, Smith JR, Thomas WB, Casimir RH: Large anaplastic spinal B-cell lymphoma in a cat. Vet Clin Pathol; 2008 Dec;37(4):389-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large anaplastic spinal B-cell lymphoma in a cat.
  • A left axillary mass was identified, and the results of fine needle aspiration cytology indicated malignant round cell neoplasia of possible histiocytic origin.
  • The initial histologic diagnosis was anaplastic sarcoma, but immunohistochemical results indicated the cells were CD20+ and CD45R+ and CD3-, compatible with a diagnosis of B-cell lymphoma.
  • Clonality of the B-cell population could not be demonstrated using PCR testing for antigen receptor gene rearrangement.
  • To the authors' knowledge, this is the first reported case of a feline spinal anaplastic B-cell lymphoma exhibiting bi- and multinucleated cells.
  • The prognostic significance of this cell morphology and immunophenotype is unknown.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet Clin Pathol. 2008 Dec;37(4):360-2 [19055569.001]
  • (PMID = 19055573.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Kost CB, Holden JT, Mann KP: Marginal zone B-cell lymphoma: a retrospective immunophenotypic analysis. Cytometry B Clin Cytom; 2008 Sep;74(5):282-6
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal zone B-cell lymphoma: a retrospective immunophenotypic analysis.
  • BACKGROUND: Marginal zone B-cell lymphoma (MZL) comprises three related yet biologically distinct subtypes--splenic MZL (SMZL), nodal MZL (NMZL), and extranodal MZL of MALT type (MALT).
  • In cases without adequate morphology, immunophenotypic characterization by flow cytometric immunophenotyping (FCI) relies heavily on exclusion of other low-grade lymphomas.
  • We compared these to follicular lymphoma (FL) as we were specifically interested in differentiating MZL from CD10 negative FL.
  • CONCLUSIONS: MZL expresses typical pan-B-cell antigens.
  • [MeSH-major] Immunophenotyping / methods. Lymphoma, B-Cell, Marginal Zone / diagnosis
  • [MeSH-minor] Antibodies, Neoplasm / immunology. Antigens, Neoplasm / immunology. Fluorescence. Humans. Lymphoma, Follicular / immunology. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500740.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm
  •  go-up   go-down


64. Pazur M, Jelić-Puskarić B, Planinc-Peraica A, Vrhovac R, Kardum-Skelin I, Jaksić B: T lymphoblastic leukaemia with an unusual Burkitt lymphoma morphology--a case report. Coll Antropol; 2010 Jun;34(2):675-8
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T lymphoblastic leukaemia with an unusual Burkitt lymphoma morphology--a case report.
  • Precursor T-cell acute lymphoblastic leukaemia (T-ALL)/lymphoma (T-LBL) is a neoplasm with cytological features that include blast cells of medium size, high nuclear cytoplasmic ratio and inconspicuous nucleoli, which are usually TdT (Terminal Deoxynucleotidyl Transferase) positive and variably express T-cell markers.
  • Bone marrow aspiration revealed 87% and peripheral blood 41% of lymphoblasts with cytoplasmic vacuoles which suggested Burkitt lymphoma (BL) morphology.
  • This excluded Burkitt lymphoma and led to diagnosis of T-ALL.
  • The patient was submitted to two cycles of chemotherapy, autologous stem cell transplantation, and intrathecal chemotherapy, but he died after 10 months because of disease complications (lung aspergillosis and pleural effusion).
  • Our case report showed how morphology alone can be misleading and sometimes is not enough in diagnosing ALL.
  • Beside morphologic criteria, setting correct diagnosis depends on identification of immunophenotype by flow cytometry and cytogenetic-molecular abnormalities.
  • [MeSH-major] Burkitt Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Antigens, CD2 / analysis. Bone Marrow / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Fatal Outcome. Humans. Karyotyping. Lymphocytes / pathology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698152.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antigens, CD2
  •  go-up   go-down


65. Ponce F, Marchal T, Magnol JP, Turinelli V, Ledieu D, Bonnefont C, Pastor M, Delignette ML, Fournel-Fleury C: A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Vet Pathol; 2010 May;47(3):414-33
SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology.
  • This study reports cytomorphological, histomorphological, and immunological characterization of 608 biopsy cases of canine malignant lymphoma, with epidemiological and clinical data, collected from 7 French veterinary pathology laboratories.
  • It compares morphological characteristics of malignant lymphoma in canines, per the updated Kiel classification system, with those reported in humans, per the World Health Organization (WHO) classification system.
  • Immunohistochemistry confirmed 63.8% B-cell (CD3-, CD79a+), 35.4% T-cell (CD3+, CD79a-), and 0.8% null-cell (CD3-, CD79a-) lymphomas.
  • Most B-cell cases (38.49%) were of high-grade centroblastic polymorphic subtype; most T-cell cases (8.55%), high-grade pleomorphic mixed and large T-cell lymphoma subtypes.
  • Some B-cell tumors showed morphologic characteristics consistent with follicular lymphomas and marginal zone lymphomas per the Revised European American Classification of Lymphoid Neoplasms and WHO canine classification systems and the WHO human classification system.
  • Unusual high-grade B-cell subtypes included an atypical high-grade small B-cell lymphoma (0.66%), Burkitt-type B-cell lymphoma (1.64%), plasmacytoid lymphoma (0.99%), and mediastinal anaplastic large B-cell lymphoma (0.16%).
  • Unusual T-cell subtypes included a previously undescribed high-grade canine immunoblastic T-cell type (1.15%), a rare low-grade prolymphocytic T-cell lymphoma (0.16%), and a recently described high-grade canine T-cell entity--aggressive granulocytic large-cell lymphoma (0.16%).
  • Canine primary cutaneous malignant lymphoma subtypes were present (11.84%).
  • There was no significant difference between B- and T-cell malignant lymphoma in regard to canine age and sex.
  • A significant overrepresentation of Boxers (24.19%) was found for T-cell lymphomas.
  • [MeSH-major] Dog Diseases / pathology. Lymphoma / veterinary
  • [MeSH-minor] Animals. Dogs. France / epidemiology. Humans. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / veterinary. Lymphoma, T-Cell / epidemiology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / veterinary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20472804.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Reichard KK, McKenna RW, Kroft SH: ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol; 2007 Mar;20(3):310-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.
  • We report detailed clinical and pathologic features of four cases of anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL), a rare entity with only 29 currently reported cases.
  • Biopsies from four adult patients aged 41, 49, 53, and 71 years (three lymph nodes and one nasopharyngeal mass) exhibited immunoblastic/plasmablastic morphology.
  • [MeSH-major] Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277765.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


67. Adam P, Steinlein C, Schmid M, Haralambieva E, Stocklein H, Leich E, Rosenwald A, Muller-Hermelink HK, Ott G: Characterization of chromosomal aberrations in diffuse large B-cell lymphoma (DLBL) by G-banding and spectral karyotyping (SKY). Cytogenet Genome Res; 2006;114(3-4):274-8
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of chromosomal aberrations in diffuse large B-cell lymphoma (DLBL) by G-banding and spectral karyotyping (SKY).
  • Cytogenetic chromosome analysis by classical G-banding was supplemented by spectral karyotyping (SKY) in 12 cases of diffuse large B-cell lymphoma (DLBL).
  • SKY is a fluorescence in-situ-based, genome-wide screening technique allowing identification of genetic material even in highly condensed metaphase chromosomes of poor morphology.
  • [MeSH-major] Chromosome Aberrations. Chromosome Banding. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16954666.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


68. Badea M, Dobrea C, Badea D, Genunche-Dumitrescu A, Mitruţ P, Duţă D: The composite lymphoma: chronic lymphocytic leukemia--classic Hodgkin's lymphoma. Rom J Morphol Embryol; 2010;51(2):353-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The composite lymphoma: chronic lymphocytic leukemia--classic Hodgkin's lymphoma.
  • The composite lymphoma (CL) is defined by the presence in the same tissue or organ of two distinct histological aspects of non-Hodgkin's lymphoma (NHL), or NHL and Hodgkin's lymphoma (HL).
  • The biopsy of a left cervical lymph node reveal a CL: a histological and immunophenotypic aspect of HL-mixed cellularity (CD15+, CD30+, CD20-) and a diffuse small cell infiltrate which meet the criteria for B-CLL (CD20+, CD23+, and CD5+).
  • The EBV-role in HL-pathogeny is related to the way of salvage or/and initiation of a clonal process in a GC-cell which has major deletions in the variable part of IgH.
  • [MeSH-major] Hodgkin Disease / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495755.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


69. Lurie DM, Milner RJ, Suter SE, Vernau W: Immunophenotypic and cytomorphologic subclassification of T-cell lymphoma in the boxer breed. Vet Immunol Immunopathol; 2008 Sep 15;125(1-2):102-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic and cytomorphologic subclassification of T-cell lymphoma in the boxer breed.
  • The boxer breed is at high risk for developing lymphoma and, in contrast to the general canine population, is predisposed to the T-cell variant of the disease.
  • The purpose of this study was to more accurately classify lymphoma in this breed.
  • Clinical, cytomorphologic and immunophenotypic data were examined in 43 boxers with lymphoma.
  • Of the 40 immunophenotyped samples, 34 (85%) were T-cell, 5 (12.5%) were B-cell and 1 was a non-B-cell non-T-cell lymphoma.
  • Immunophenotypic subtyping was done on prospectively collected T-cell lymphoma samples (n=22) to differentiate CD4 (helper) from CD8 (cytotoxic) T-cell origin as well as to determine the T-cell receptor (TCR) expression (TCRalphabeta vs. TCRdeltagamma).
  • According to this scheme, 17/22 samples were classified as lymphoblastic, 2/22 as large cell peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), 2/22 as large granular lymphoma (LGL) high-grade and 1/22 as small lymphocytic.
  • The results of this study indicate that lymphoma in the boxer breed is a disease comprised predominantly of TCRalphabeta+, CD4+ (helper) T-cells with lymphoblastic (high-grade) morphology.
  • [MeSH-major] Dog Diseases / classification. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / veterinary
  • [MeSH-minor] Animals. Antigens, CD4 / blood. Antigens, CD4 / immunology. Antigens, CD8 / blood. Antigens, CD8 / immunology. Biopsy, Fine-Needle / veterinary. Dogs. Female. Genetic Predisposition to Disease. Immunohistochemistry / veterinary. Immunophenotyping / veterinary. Kaplan-Meier Estimate. Male. Prospective Studies. Receptors, Antigen, T-Cell, alpha-beta / blood. Receptors, Antigen, T-Cell, alpha-beta / immunology. Receptors, Antigen, T-Cell, gamma-delta / blood. Receptors, Antigen, T-Cell, gamma-delta / immunology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18579219.001).
  • [ISSN] 0165-2427
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


70. Hartmann S, Hansmann ML: [Grayzone lymphoma. Clinical relevance]. Pathologe; 2010 Feb;31(1):42-9
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Grayzone lymphoma. Clinical relevance].
  • Malignant lymphomas are classified into different entities according to their morphology, immunohistochemical parameters and clinical behavior.
  • Several important pathogenetic events can be assigned to certain lymphoma entity types.
  • Nevertheless, some cases present overlapping morphologic and immunohistochemical characteristics and a clear-cut diagnosis cannot be made.
  • This is particularly the case with aggressive lymphomas for which a clear distinction cannot be made between the entities of diffuse large cell lymphoma/Burkitt lymphoma or primary mediastinal B cell lymphoma/classic Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma / classification. Lymphoma / pathology
  • [MeSH-minor] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. B-Lymphocytes / pathology. Biomarkers, Tumor / genetics. Burkitt Lymphoma / classification. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / genetics. Burkitt Lymphoma / pathology. DNA Mutational Analysis. Diagnosis, Differential. Hodgkin Disease / classification. Hodgkin Disease / drug therapy. Hodgkin Disease / genetics. Hodgkin Disease / pathology. Humans. Immunoenzyme Techniques. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / classification. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / genetics. Mediastinal Neoplasms / pathology. Molecular Diagnostic Techniques. Rituximab. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1165-72 [2566907.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):958-67 [19692684.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1523-9 [18441328.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5573-9 [19786664.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):141-51 [16645199.001]
  • [Cites] J Exp Med. 2008 Sep 29;205(10):2251-68 [18794340.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5494-502 [19706817.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):243-53 [12507907.001]
  • [Cites] Leukemia. 2007 Apr;21(4):780-7 [17375124.001]
  • [Cites] J Hematop. 2009 Jul;2(2):89-95 [19669187.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4340-6 [16908931.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1318-26 [18641027.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2679-84 [16532038.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3387-90 [17652621.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1411-21 [16224207.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):229-34 [12067685.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Lancet Oncol. 2005 Apr;6(4):249-51 [15811621.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] Blood. 2009 Nov 12;114(20):4503-6 [19734449.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] J Exp Med. 2009 May 11;206(5):981-9 [19380639.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):489-95 [12478664.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2226-9 [18754028.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Blood. 2009 Oct 22;114(17):3533-7 [19704118.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2535-42 [15572583.001]
  • (PMID = 20013122.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 37
  •  go-up   go-down


71. Magro CM, Nash JW, Werling RW, Porcu P, Crowson N: Primary cutaneous CD30+ large cell B-cell lymphoma: a series of 10 cases. Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):7-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD30+ large cell B-cell lymphoma: a series of 10 cases.
  • BACKGROUND: White CD30 expression is described in extracutaneous diffuse large B-cell lymphomas, a primary cutaneous B-cell lymphoma (PCBCL) equivalent is not well defined.
  • METHODS: Between June 1999 and July 2002 the authors encountered 10 patients with CD30+ PCBCLs of the large cell type.
  • Skin biopsies showed a background of T-cell-rich reactive lymphoid hyperplasia in 7 of 10 patients, with variable granulomatous inflammation in 5 cases.
  • In the remaining patients the reactive infiltrate defined the dominant cell population.
  • In two cases associated with methotrexate therapy, Epstein-Barr virus expression was observed amid the neoplastic cell populace.
  • CONCLUSIONS: CD30+ PCBCL is a distinctive form of B-cell lymphoma presenting in elderly patients and can be associated with a very good prognosis.

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540723.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


72. Hsiao SC, Ichinohasama R, Lin SH, Liao YL, Chang ST, Cho CY, Chuang SS: EBV-associated diffuse large B-cell lymphoma in a psoriatic treated with methotrexate. Pathol Res Pract; 2009;205(1):43-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-associated diffuse large B-cell lymphoma in a psoriatic treated with methotrexate.
  • Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is a lymphoid proliferation or lymphoma in a patient immunosuppressed with MTX, which is usually administered for treating autoimmune diseases.
  • The diffuse and polymorphic lymphoid infiltrate consisted predominantly of immunoblasts and plasmablasts expressing B-cell markers, CD138, Epstein-Barr virus (EBV)-LMP1, and EBNA2, and these were monotypic for kappa light chain.
  • The tumors are diffuse large B-cell lymphomas with immunoblastic morphology, and frequently show plasmacytic differentiation.
  • [MeSH-major] Dermatologic Agents / adverse effects. Epstein-Barr Virus Infections / chemically induced. Immunosuppressive Agents / adverse effects. Lymphoma, Large B-Cell, Diffuse / chemically induced. Lymphoma, Large B-Cell, Diffuse / virology. Methotrexate / adverse effects. Psoriasis / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18951733.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Immunosuppressive Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 22
  •  go-up   go-down


73. Chen YP, Yen YS, Chen TY, Yen CL, Shieh CC, Chang KC: Systemic Mycobacterium kansasii infection mimicking peripheral T-cell lymphoma. APMIS; 2008 Sep;116(9):850-8
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic Mycobacterium kansasii infection mimicking peripheral T-cell lymphoma.
  • However, it may mimic malignancy on account of the clinical manifestations or the morphology of atypical lymphocytes with epithelioid histiocytes.
  • The latter can be found in some types of lymphomas, especially T-cell lymphoma.
  • Bone marrow was also involved in the same process in one case and T-cell lymphoma with lymphoepithelioid features was the initial impression.
  • However, further studies reported germline arrangements of T-cell receptor genes, presence of acid-fast bacilli, and recovery of M. kansasii in culture.
  • This report describes two infectious cases with small aggregates of epithelioid histiocytes and atypical lymphocytes mimicking peripheral T-cell lymphoma; and such cases may become more common as the number of immunosuppressed hosts is increasing worldwide.
  • We have reviewed the literature and summarized useful morphologic criteria for differentiation.
  • [MeSH-major] Lymphadenitis / diagnosis. Lymphoma, T-Cell / diagnosis. Mycobacterium Infections, Nontuberculous / diagnosis. Mycobacterium kansasii / isolation & purification

  • Genetic Alliance. consumer health - Mycobacterium Kansasii.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024609.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


74. Beltran B, Castillo J, Salas R, Quiñones P, Morales D, Hurtado F, Riva L, Winer E: ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol; 2009;2:11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.
  • BACKGROUND: Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL) is a rare lymphoma with several clinicopathological differences from ALK-positive anaplastic large cell lymphoma (ALCL).
  • All cases exhibited plasmablastic morphology.
  • CONCLUSION: ALK-DLBCL is a distinct variant of DLBCL with plasmacytic differentiation, which is characterized by a bimodal age incidence curve, primarily nodal involvement, plasmablastic morphology, lack of expression of CD20, aggressive behavior and poor response to standard therapies, although some cases can have prolonged survival as the cases reported in this study.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / metabolism. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2009 Jan;40(1):75-82 [18755494.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Am J Clin Pathol. 2001 Mar;115(3):396-403 [11242796.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):828-32 [12920229.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1285-8 [15492998.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Pol J Pathol. 2005;56(1):37-45 [15921012.001]
  • [Cites] Curr Oncol Rep. 2005 Sep;7(5):357-63 [16091196.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1839-40 [16107887.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):390-1 [16086416.001]
  • [Cites] Rinsho Ketsueki. 2005 Jul;46(7):501-6 [16440742.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):649-53 [15852431.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):493-505 [16794633.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2006 Sep;35(9):529-34 [17134546.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):940-5 [17509395.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):166-9 [17635242.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2573-80 [18089849.001]
  • [Cites] J Cell Mol Med. 2008 Jan-Feb;12(1):126-44 [18039352.001]
  • [Cites] Korean J Lab Med. 2008 Apr;28(2):89-94 [18458503.001]
  • [Cites] Biochem J. 2008 Jun 15;412(3):415-23 [18498251.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):108-13 [18220322.001]
  • (PMID = 19250532.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 39
  • [Other-IDs] NLM/ PMC2651189
  •  go-up   go-down


75. Mitani S, Kamata H, Fujiwara M, Aoki N, Okada S, Watanabe M, Tango T, Mori S: Missense mutation with/without nonsense mutation of the p53 gene is associated with large cell morphology in human malignant lymphoma. Pathol Int; 2007 Jul;57(7):430-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Missense mutation with/without nonsense mutation of the p53 gene is associated with large cell morphology in human malignant lymphoma.
  • Missense mutations were found in two diffuse large B-cell lymphomas (DLBL) and one peripheral T-cell lymphoma (unspecified).
  • Double transversion missense and nonsense mutations were detected in one DLBL and one adult T-cell leukemia/lymphoma.
  • Cytomorphometric analysis was therefore conducted by measuring the gross area of 100 lymphoma cell nuclei in 44 cases and the results were compared between lymphomas harboring p53 missense mutation with/without nonsense mutation and lymphomas harboring p53 silent mutation or lacking mutation.
  • This result suggests that p53 mutation might induce enlargement of neoplastic cell nuclei by some molecular mechanism.
  • [MeSH-major] Codon, Nonsense. Genes, p53 / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Mutation, Missense
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Nucleus / pathology. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587242.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / DNA, Neoplasm
  •  go-up   go-down


76. Zhang S, Nong L, Ren YL, Li T: [Clinicopathologic study of hepatosplenic T-cell lymphoma]. Beijing Da Xue Xue Bao; 2008 Aug 18;40(4):387-91
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of hepatosplenic T-cell lymphoma].
  • OBJECTIVE: To explore the clinicopathologic features and diagnostic criteria of hepatosplenic T-cell lymphoma (HSTCL).
  • METHODS: Three cases of HSTCL were searched for morphology, immunophenotypings, Epstein-Barr virus (EBV) in situ hybridization and T-cell receptorgamma (TCRgamma) gene rearrangement.
  • CONCLUSION: HSTCL is a rare entity which is classified into peripheral T cell lymphomas.
  • And it is regarded as a subset of unactived cytotoxic T-cell lymphomas.
  • [MeSH-major] Liver Neoplasms / pathology. Lymphoma, T-Cell, Peripheral / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD3 / metabolism. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Herpesvirus 4, Human. Humans. Immunophenotyping. Male. Poly(A)-Binding Proteins / genetics. Poly(A)-Binding Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677385.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Poly(A)-Binding Proteins; 0 / TIA1 protein, human
  •  go-up   go-down


77. van de Water JM, Cillessen SA, Visser OJ, Verbeek WH, Meijer CJ, Mulder CJ: Enteropathy associated T-cell lymphoma and its precursor lesions. Best Pract Res Clin Gastroenterol; 2010 Feb;24(1):43-56
Genetic Alliance. consumer health - Enteropathy-Associated T-Cell Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteropathy associated T-cell lymphoma and its precursor lesions.
  • Enteropathy Associated T-cell Lymphoma (EATL) is an intestinal tumour of intra-epithelial lymphocytes.
  • Based on morphology, immunohistochemistry and genetic profile EATL can be divided into two groups.
  • EATL type I is a large cell lymphoma which is highly associated with Coeliac Disease (CD) and mostly presents with malabsorption, weight loss and CD-related symptoms.
  • Nowadays, most EATL patients are treated with chemotherapy mostly preceded by resection of the tumour and followed by stem cell transplantation.
  • [MeSH-major] Intestinal Diseases / complications. Intestinal Neoplasms / etiology. Lymphoma, T-Cell / etiology. Precancerous Conditions / etiology
  • [MeSH-minor] Celiac Disease / complications. Chemotherapy, Adjuvant. Digestive System Surgical Procedures. Humans. Inflammatory Bowel Diseases / complications. Intestinal Obstruction / complications. Intestinal Perforation / complications. Risk Factors. Stem Cell Transplantation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20206108.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 119
  •  go-up   go-down


78. Zhang YN, Zhou XG, Zhang SH, Wang P, Zhang CH, Huang SF: [Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2005 Apr;34(4):193-7
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms].
  • OBJECTIVE: To describe the relative frequency, morphologic features, immunophenotype and clinical data of different types of B-cell non-Hodgkin lymphoma (B-NHL) and to evaluate the practical application of the 2001 World Health Organization (WHO) classification of lymphoid neoplasms.
  • Diffuse large B-cell lymphoma, extranodal marginal zone lymphoma and follicular lymphoma were the commonest subtypes, accounting for 51.2% (189 cases), 14.9% (55 cases) and 10.6% (39 cases) of all cases respectively.
  • B-cell prolymphocytic leukemia and hairy cell leukemia were not identified.
  • When comparing the diagnosis based on morphologic examination alone with the diagnosis based on both morphology and immunophenotype, there was a 80% concordance rate.
  • CONCLUSIONS: Amongst cases of B-NHL, diffuse large B-cell lymphoma is the commonest subtype, followed by MALToma and follicular lymphoma.
  • While morphologic examination forms the basis for lymphoma diagnosis, immunohistochemical study also plays an important role in further subtyping.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / classification

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091170.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD43; 0 / Antigens, CD79
  •  go-up   go-down


79. Ohno H, Nishikori M, Haga H, Isoda K: Epstein-Barr virus-positive diffuse large B-cell lymphoma carrying a t(9;14)(p13;q32) translocation. Int J Hematol; 2009 Jun;89(5):704-8
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positive diffuse large B-cell lymphoma carrying a t(9;14)(p13;q32) translocation.
  • We, herein, report a 75-year-old man with lymphoma who initially presented with disseminated disease involving the lung, followed by temporal regression, and finally died of disease progression.
  • Lymph-node biopsy showed a morphology of diffuse large B-cell lymphoma (DLBCL), containing CD30(+) Reed-Sternberg-like cells.
  • The lymphoma cells were stained by in situ hybridization (ISH) for Epstein-Barr virus (EBV)-encoded RNA, and the presence of the EBV genome was confirmed by the polymerase chain reaction.
  • A cytogenetic study showed that the lymphoma cells carried a t(9;14)(p13;q32) translocation, and rearrangement of the PAX5 gene was determined by fluorescence ISH using a split signal probe.
  • [MeSH-major] Herpesvirus 4, Human. Lymphoma, Large B-Cell, Diffuse / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19430986.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Kodama A, Sakai H, Kobayashi K, Mori T, Maruo K, Kudo T, Yanai T, Masegi T: B-cell intestinal lymphoma with Mott cell differentiation in a 1-year-old miniature Dachshund. Vet Clin Pathol; 2008 Dec;37(4):409-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell intestinal lymphoma with Mott cell differentiation in a 1-year-old miniature Dachshund.
  • The morphologic features, immunophenotype, and IgH gene rearrangement verified the lymphoid cells were neoplastic (mature cell type) and had a B-cell phenotype, with evidence of immunoglobulin production and differentiation into Mott cells.
  • This case was unusual because of the age of the dog and because most intestinal lymphomas are T-cell phenotype.
  • The Mott cell morphology also differed from typical mature B-cell lymphoma types and may be a unique B-cell lymphoma variant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet Clin Pathol. 2008 Dec;37(4):360-2 [19055569.001]
  • (PMID = 19055576.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


81. Coupland SE, Chan CC, Smith J: Pathophysiology of retinal lymphoma. Ocul Immunol Inflamm; 2009 Jul-Aug;17(4):227-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathophysiology of retinal lymphoma.
  • Retinal lymphoma, the most common form of intraocular lymphoma, is a high-grade malignancy, usually of B-cell type, and is associated with a poor prognosis because of frequent central nervous system (CNS) involvement.
  • The neoplastic B-cells of retinal lymphoma have a characteristic morphology and immunophenotype, express certain chemokines and chemokine receptors, and produce interleukins (IL), e.g. IL-10.
  • Immunophenotyping and somatic mutation analysis suggest derivation of most retinal lymphomas from an early post-germinal centre B-cell.
  • Further investigations, such as gene expression profiling, are required to identify oncogenic pathways potentially involved in retinal lymphoma development, and to identify new prognostic/therapeutic markers for this tumor.
  • [MeSH-major] Lymphoma / pathology. Lymphoma / physiopathology. Retinal Neoplasms / pathology. Retinal Neoplasms / physiopathology
  • [MeSH-minor] Chemokines / metabolism. Fundus Oculi. Genotype. Humans. Immunophenotyping. Interleukin-10 / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / physiopathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / physiopathology. Prognosis. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 2007 Sep;114(3):271-6 [17641901.001]
  • [Cites] Br J Haematol. 2007 Sep;138(6):749-55 [17760806.001]
  • [Cites] Br J Ophthalmol. 2008 Feb;92(2):297-9 [18227216.001]
  • [Cites] Leukemia. 2008 Feb;22(2):400-5 [17989719.001]
  • [Cites] Am J Ophthalmol. 2009 May;147(5):764-5 [19376328.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:275-92 [14971583.001]
  • [Cites] Br J Haematol. 2004 Feb;124(4):469-73 [14984496.001]
  • [Cites] Ophthalmologe. 2004 Jan;101(1):87-98 [14986704.001]
  • [Cites] Ocul Immunol Inflamm. 2004 Mar;12(1):7-16 [15209459.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Clin Lymphoma. 2004 Jun;5(1):19-28 [15245604.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3498-506 [15337798.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] Ocul Immunol Inflamm. 2008 Jan-Feb;16(1):29-33 [18379939.001]
  • [Cites] Int J Lab Hematol. 2008 Jun;30(3):230-9 [18479302.001]
  • [Cites] Surv Ophthalmol. 2008 May-Jun;53(3):285-95 [18501272.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3777-84 [18559596.001]
  • [Cites] Jpn J Ophthalmol. 2008 May-Jun;52(3):167-74 [18661266.001]
  • [Cites] Clin Experiment Ophthalmol. 2008 Aug;36(6):564-78 [18954321.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4738-45 [18552383.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2107-15 [19276283.001]
  • [Cites] Am J Ophthalmol. 2009 May;147(5):886-94, 894.e1 [19243734.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5242-7 [11431365.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2285-90 [11895757.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Pathologe. 2002 Jul;23(4):284-91 [12185781.001]
  • [Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]
  • [Cites] Ophthalmology. 2003 Feb;110(2):421-6 [12578791.001]
  • [Cites] Clin Experiment Ophthalmol. 2003 Apr;31(2):155-8 [12648051.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1777-85 [12724484.001]
  • [Cites] Ophthalmology. 2003 Aug;110(8):1671-2 [12917196.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2003 Oct;241(10):860-70 [14605902.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):835-53 [3286832.001]
  • [Cites] Arch Ophthalmol. 1989 Sep;107(9):1349-53 [2675806.001]
  • [Cites] J Exp Med. 1989 Dec 1;170(6):2081-95 [2531194.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1890-3 [1371884.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1289-98 [1325212.001]
  • [Cites] Eur J Immunol. 1992 Nov;22(11):2937-42 [1330578.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):231-6 [8508412.001]
  • [Cites] Blood. 1993 Oct 1;82(7):2261-2 [8400277.001]
  • [Cites] J Clin Invest. 1994 Jan;93(1):424-8 [8282815.001]
  • [Cites] J Immunol. 1995 Jan 15;154(2):718-29 [7814878.001]
  • [Cites] Am J Ophthalmol. 1995 Nov;120(5):671-3 [7485372.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2918-29 [8639912.001]
  • [Cites] J Immunol. 1997 May 1;158(9):4045-51 [9126962.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1157-60 [9298057.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1738-46 [10477699.001]
  • [Cites] Br J Ophthalmol. 2004 Dec;88(12):1498-9 [15548797.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Nov;242(11):901-13 [15565454.001]
  • [Cites] Br J Ophthalmol. 2005 Feb;89(2):238-9 [15665359.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Feb;46(2):415-9 [15671263.001]
  • [Cites] J Neurol Sci. 2005 Feb 15;228(2):143-7 [15694195.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2005 Mar;243(3):189-97 [15806372.001]
  • [Cites] Blood. 2005 Jul 1;106(1):384-5 [15967804.001]
  • [Cites] Arch Pathol Lab Med. 2005 Aug;129(8):1050-3 [16048400.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1392-9 [15870177.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):739-49, viii [16083834.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3507-14 [16186327.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Nov;46(11):3957-64 [16249468.001]
  • [Cites] Blood. 2006 Jan 1;107(1):190-6 [16150948.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1152-6 [16489068.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):311-7 [16492805.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2750-6 [16799010.001]
  • [Cites] Curr Opin Ophthalmol. 2006 Dec;17(6):523-31 [17065920.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10586-93 [17079483.001]
  • [Cites] Neurosurg Focus. 2006;21(5):E1 [17134111.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1762-7 [15350334.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2077-86 [10595937.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2098-102 [10617422.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Ophthalmology. 2001 Mar;108(3):426-7 [11237883.001]
  • [Cites] Annu Rev Immunol. 2001;19:683-765 [11244051.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3992-4 [11389046.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):805-12 [17327602.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Mar;66(3):230-7 [17356384.001]
  • [Cites] Am J Clin Pathol. 2007 Apr;127(4):633-41 [17369141.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):5042-54 [17510437.001]
  • [Cites] Int Ophthalmol. 2007 Aug;27(4):241-50 [17440686.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3223-9 [17591892.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3253-9 [17591896.001]
  • (PMID = 19657975.001).
  • [ISSN] 1744-5078
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokines; 130068-27-8 / Interleukin-10
  • [Number-of-references] 90
  • [Other-IDs] NLM/ NIHMS138865; NLM/ PMC2769503
  •  go-up   go-down


82. Gualco G, Chioato L, Van Den Berg A, Weiss LM, Bacchi CE: Composite lymphoma: EBV-positive classic Hodgkin lymphoma and peripheral T-cell lymphoma: a case report. Appl Immunohistochem Mol Morphol; 2009 Jan;17(1):72-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite lymphoma: EBV-positive classic Hodgkin lymphoma and peripheral T-cell lymphoma: a case report.
  • Of all possible combinations between non-Hodgkin lymphomas, B cell or T cell, and Hodgkin lymphoma, the least frequent are the ones combining T-cell non-Hodgkin lymphoma and classic Hodgkin lymphoma.
  • A cervical lymph node biopsy revealed a composite lymphoma with classic Hodgkin lymphoma and peripheral T-cell lymphoma components.
  • The other component was more abundant and comprised polymorphic medium-sized cells with convoluted nuclei; CD3, CD5, CD2, and CD4 expression; and negativity for CD30, cytotoxic granules, and B-cell markers.
  • Clonal T-cell receptor gamma and beta gene rearrangements were detected in the T-cell component, whereas monoclonal immunoglobulin H gene rearrangement was found in the Hodgkin cells.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115485.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


83. Takeshita A, Shinjo K, Yamakage N, Ono T, Hirano I, Matsui H, Shigeno K, Nakamura S, Tobita T, Maekawa M, Ohnishi K, Sugimoto Y, Kiyoi H, Naoe T, Ohno R: CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol; 2009 Jun;146(1):34-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
  • The effect of CMC-544, a calicheamicin-conjugated anti-CD22 monoclonal antibody, was analysed in relation to CD22 and P-glycoprotein (P-gp) in B-cell chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) in vitro.
  • The cell lines used were CD22-positive parental Daudi and Raji, and their P-gp positive sublines, Daudi/MDR and Raji/MDR.
  • Cells obtained from 19 patients with B-cell CLL or NHL were also used.
  • The effect of CMC-544 was analysed by viable cell count, morphology, annexin-V staining, and cell cycle distribution.
  • A dose-dependent, selective cytotoxic effect of CMC-544 was observed in cell lines that expressed CD22.
  • Our findings will help to predict the clinical effectiveness of this drug on these B-cell malignancies, suggesting a beneficial effect with combined use of CMC-544 and MDR modifiers.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Cell Count. Cell Line, Transformed. Cell Line, Tumor. Cyclosporins / therapeutic use. Dose-Response Relationship, Drug. Drug Resistance, Multiple / drug effects. Drug Resistance, Neoplasm. Flow Cytometry. Humans. Immunosuppressive Agents / therapeutic use. Jurkat Cells. P-Glycoprotein / analysis. P-Glycoprotein / antagonists & inhibitors. P-Glycoprotein / metabolism. Quinolines / therapeutic use. Sialic Acid Binding Ig-like Lectin 2 / analysis. Sialic Acid Binding Ig-like Lectin 2 / immunology. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388933.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Cyclosporins; 0 / Immunosuppressive Agents; 0 / Inotuzumab Ozogamicin; 0 / P-Glycoprotein; 0 / Quinolines; 0 / Sialic Acid Binding Ig-like Lectin 2; 0BJK6B565B / dofequidar; 121584-18-7 / valspodar
  •  go-up   go-down


84. Naeem S, Bukhari MH, Khurshid I, Hameed A: Bone marrow involvement in systemic ALK+ anaplastic large cell lymphoma: morphological resemblance with Hodgkin's lymphoma. J Coll Physicians Surg Pak; 2006 Feb;16(2):148-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow involvement in systemic ALK+ anaplastic large cell lymphoma: morphological resemblance with Hodgkin's lymphoma.
  • Diagnosis of anaplastic large cell lymphoma was made on lymph node biopsy and confirmed by immunohistochemistry using a panel of monoclonal antibodies including ALK-1.
  • Bone marrow aspiration revealed the presence of large lymphoma cells and trephine biopsy showed interstitial involvement.
  • All these features resulted in a strong resemblance of the morphology with Hodgkin's lymphoma.
  • [MeSH-major] Activin Receptors, Type II / metabolism. Bone Marrow / pathology. Hodgkin Disease / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499814.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


85. Mao Z, Quintanilla-Martinez L, Raffeld M, Richter M, Krugmann J, Burek C, Hartmann E, Rudiger T, Jaffe ES, Müller-Hermelink HK, Ott G, Fend F, Rosenwald A: IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol; 2007 Oct;31(10):1605-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
  • Approximately 5% of B-cell chronic lymphocytic leukemia (B-CLL) patients develop a secondary aggressive lymphoma, usually of diffuse large B-cell type (DLBCL), termed Richter's transformation (RT).
  • Rarely, classic Hodgkin lymphoma (HL) is observed.
  • Published small series suggest that tumor cells in DLBCL and HL can be clonally identical to the B-CLL clone or arise as an independent, secondary lymphoma.
  • We describe the morphology, immunophenotype, and clinical features of 34 classic RT patients with DLBCL, 6 cases of B-CLL with HL, and 8 cases with scattered CD30-positive Hodgkin and Reed-Sternberg (HRS)-like cells.
  • In classic RT, 18/23 B-CLL cases (78%) showed clonal progression to DLBCL with identical IgVH sequences in both lymphoma components, whereas in 5 cases (22%) the DLBCL was clonally unrelated.
  • [MeSH-major] Hodgkin Disease / genetics. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Clone Cells. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Gene Rearrangement, B-Lymphocyte. Humans. Lasers. Male. Microdissection. Middle Aged. Polymerase Chain Reaction. Somatic Hypermutation, Immunoglobulin


86. Hassan R, Felisbino F, Stefanoff CG, Pires V, Klumb CE, Dobbin J, Seuánez HN, Renault IZ: Burkitt lymphoma/leukaemia transformed from a precursor B cell: clinical and molecular aspects. Eur J Haematol; 2008 Mar;80(3):265-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma/leukaemia transformed from a precursor B cell: clinical and molecular aspects.
  • Burkitt lymphoma/leukaemia (BL/L) is a heterogeneous disease with respect to epidemiological patterns and cell origin.
  • The occurrence of BL/L with an immature phenotype raises the question whether this phenotype might be a consequence of early B-cell transformation or, alternatively, a secondary feature of transformed, mature B cells.
  • Here we describe the case of a 4-yr-old child with BL/L and FAB L3 morphology, with phenotypic and genotypic characteristics of a CD10+ precursor B-cell acute lymphoid leukaemia (ALL) associated with t(8;14)(q24;q32).
  • Molecular analysis showed expression of RAG1 and RAG2 and an unmutated VDJCmu immunoglobulin rearrangement coinciding with a lack of AICDA expression, indicating an immature B-cell origin.
  • His clinical response suggested that FAB L3 ALL with MYC rearrangement and an aberrant precursor B-cell phenotype is clinically similar to BL/L.
  • This case also allowed us to refine the description of cellular and molecular variants of BL/L regarding the cell origin and pathogenesis of this biologically heterogeneous disease.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Cell Transformation, Neoplastic / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cells, B-Lymphoid / pathology
  • [MeSH-minor] Cell Differentiation / physiology. Child, Preschool. Diagnosis, Differential. Gene Fusion. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Genes, myc. Humans. Immunoglobulin Heavy Chains / genetics. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18005389.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


87. Troxell ML, Schwartz EJ, van de Rijn M, Ross DT, Warnke RA, Higgins JP, Natkunam Y: Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma. Appl Immunohistochem Mol Morphol; 2005 Dec;13(4):297-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma is characterized by a paracortical proliferation of medium to large neoplastic T cells, often with clear cytoplasm, in a background of arborizing high endothelial venules, many surrounded by follicular dendritic cells (FDCs).
  • The authors stained a collection of 45 angioimmunoblastic T-cell lymphomas with CD21, CD23, CNA.42, cystatin A, and fascin for direct comparison of FDC staining characteristics in this setting.
  • CD21 highlighted the expected dendritic network of cell processes, within residual follicles and outside of follicles, often adjacent to proliferating vessels.
  • Cystatin A stained the cytoplasm of follicular dendritic cells within and outside of follicles; however, staining was often not sharply localized to dendritic cell processes, and scoring was further complicated by reactivity with other cell types in over half of the cases.
  • Likewise, fascin stained a variety of cell types, including strong staining of interdigitating dendritic-like cells, moderate staining of endothelial cells, and only weak staining of follicular dendritic cells within and outside of follicles.
  • Thus, CD21 remains the most reliable marker of follicular dendritic cells in angioimmunoblastic T-cell lymphoma.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280657.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Carrier Proteins; 0 / Cystatins; 0 / Cysteine Proteinase Inhibitors; 0 / Microfilament Proteins; 0 / Receptors, Complement 3d; 0 / Receptors, IgE; 146808-54-0 / fascin
  •  go-up   go-down


88. Zhang YN, Zhou XG, Zhang SH, Zheng YY, Liu WH: [Nodal marginal zone B-cell lymphoma: a clinicopathologic study of 10 cases]. Zhonghua Bing Li Xue Za Zhi; 2007 Aug;36(8):529-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nodal marginal zone B-cell lymphoma: a clinicopathologic study of 10 cases].
  • OBJECTIVE: To study the morphologic features, immunophenotype, differential diagnosis and prognosis of nodal marginal zone B-cell lymphoma (NMZL).
  • The lymphoma was composed predominantly of atypical lymphoid cells resembling centrocytes (7/10).
  • A predominance of monocytoid B-cell (2/10) or small lymphocytic (1/10) morphology was rare.
  • Differential diagnosis includes lymphoplasmacytic lymphoma, lymph node involvement by extranodal marginal zone B-cell lymphoma and T-zone hyperplasia.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980100.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


89. Traverse-Glehen A, Felman P, Callet-Bauchu E, Gazzo S, Baseggio L, Bryon PA, Thieblemont C, Coiffier B, Salles G, Berger F: A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology; 2006 Jan;48(2):162-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases.
  • AIMS: To report the clinicopathological findings of 21 cases of primary nodal marginal zone B-cell lymphoma (NMZL).
  • NMZL is a recently characterized lymphoma and few series have been published.
  • Morphological features were heterogeneous and there were some differences compared with other marginal zone B-cell lymphomas (MZL).
  • Pure monocytoid B-cell lymphomas were rare (10%) but a minor component of monocytoid B cell was observed more frequently (23%).
  • CONCLUSION: NMZL can be distinguished from splenic MZL and extranodal MZL by its aggressive morphology and disseminated disease at presentation.
  • [MeSH-major] Lymphoma, B-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405665.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


90. Kojima M, Motoori T, Iijima M, Ono T, Yoshizumi T, Matsumoto M, Masawa N, Nakamura S: Florid monocytoid B-cell hyperplasia resembling nodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue type. A histological and immunohistochemical study of four cases. Pathol Res Pract; 2006;202(12):877-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Florid monocytoid B-cell hyperplasia resembling nodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue type. A histological and immunohistochemical study of four cases.
  • A pale ring of medium-to-large cells surrounding the follicles, namely a marginal zone distribution pattern, is the key criterion for diagnosing nodal marginal zone B-cell lymphoma (NMZBL).
  • The tumor cells of NMZBL occasionally exhibit the morphology of monocytoid B-cells (MBC).
  • [MeSH-major] B-Lymphocytes / pathology. Germinal Center / pathology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Pseudolymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989959.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


91. Rudzki Z, Rucińska M, Jurczak W, Skotnicki AB, Maramorosz-Kurianowicz M, Mruk A, Piróg K, Utych G, Bodzioch P, Srebro-Stariczyk M, Włodarska I, Stachura J: ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review. Pol J Pathol; 2005;56(1):37-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
  • Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare, recently defined tumor distinct in many aspects from ALK-positive anaplastic large cell lymphoma (ALCL).
  • Histologically the tumor was diagnosed as an ALK-positive diffuse large B-cell lymphoma. with plasmablastic features.
  • Large, frequently intrasinusoidal tumor cells expressed CD138, EMA, weakly IgA and kappa, but were negative for other B-cell markers, T-cell markers and CD30.
  • The tumor showed immunoblastic/anaplastic morphology, with some Reed-Sternberg-like cells positive for ALK.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921012.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 17
  •  go-up   go-down


92. Schuetz MJ 3rd, Zafar N, Vasef MA: Instances of mantle cell lymphoma morphologically mimicking other subtypes of B-cell lymphoid proliferation. South Med J; 2009 Apr;102(4):369-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Instances of mantle cell lymphoma morphologically mimicking other subtypes of B-cell lymphoid proliferation.
  • Mantle cell lymphoma is a well-characterized category of mature B-cell lymphoma with aberrant coexpression of CD5 antigen.
  • This subtype of lymphoma is genetically defined by t(11;14) resulting in upregulation of cyclin D1 protein.
  • In clinical practice, mantle cell lymphoma is typically diagnosed based on combination of morphology, CD20/CD5 coexpression, and nuclear staining of cyclin D1 protein by immunohistochemistry.
  • Although other neoplastic processes can also be cyclin D1 positive, documentation of cyclin D1 positivity in a CD5-positive B-cell process is virtually diagnostic of mantle cell lymphoma.
  • However, on morphologic grounds, it is well known that mantle cell lymphoma can mimic other subtypes of B-cell lymphoid neoplasm.
  • We identified several unusual examples of immunohistochemically confirmed cyclin D1-positive mantle cell lymphoma with morphologic features overlapping with a wide variety of other subtypes of mature B-cell lymphomas including follicular, marginal zone, small lymphocytic and Burkitt lymphoma.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology
  • [MeSH-minor] Antigens, CD5 / metabolism. Cyclin D1 / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Interleukin-2 Receptor alpha Subunit / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19279536.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Interleukin-2 Receptor alpha Subunit; 136601-57-5 / Cyclin D1
  •  go-up   go-down


93. de Jong D, de Boer JP: Predicting transformation in follicular lymphoma. Leuk Lymphoma; 2009 Sep;50(9):1406-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting transformation in follicular lymphoma.
  • The transformation to a more aggressive phase in follicular lymphoma (FL) is clinically marked by rapidly enlarging lymph nodes, development of B-symptoms and often rapidly rising lactate dehydrogenase (LDH) levels and is the most frequent disease-related cause of death in patients with FL.
  • Mostly, the transformed phase has a morphology of diffuse large B-cell lymphoma, and more rarely the features reminiscent of Burkitt lymphoma or precursor B-lymphoblastic lymphoma are seen.
  • [MeSH-major] Cell Transformation, Neoplastic. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / pathology
  • [MeSH-minor] Disease Progression. Humans. Incidence. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Prognosis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606378.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


94. Xu Y, McKenna RW, Doolittle JE, Hladik CL, Kroft SH: The t(14;18) in diffuse large B-cell lymphoma: correlation with germinal center-associated markers and clinical features. Appl Immunohistochem Mol Morphol; 2005 Jun;13(2):116-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The t(14;18) in diffuse large B-cell lymphoma: correlation with germinal center-associated markers and clinical features.
  • The clinical and biologic relevance of the t(14;18) and features of germinal center (GC) differentiation in diffuse large B-cell lymphoma (DLBCL) remain controversial.
  • The authors examined the association of t(14;18) with GC-associated markers and clinical features in 44 de novo DLBCLs (22 nodal and 22 primary extranodal).

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894922.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


95. Yin HF, Li T: [Comparative study of heterogeneity of extranodal and nodal diffuse large B cell lymphoma]. Beijing Da Xue Xue Bao; 2007 Apr 18;39(2):158-62
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative study of heterogeneity of extranodal and nodal diffuse large B cell lymphoma].
  • OBJECTIVE: Primary nodal and extranodal diffuse large B-cell lymphoma (DLBCL) were investigated for the heterogeneity of histopathology and immunophenotype, and their relation to clinical stage, comparatively.
  • Whether E2F1 can be used as a germinal center B cell (GCB) DLBCL marker was also discussed.
  • RESULTS: Histopathologic morphology presented as: centroblastic (CB,88.8%, 87/98), immunoblastic (IB,5.1%, 5/98), anaplastic (ALCL,3.1%, 3/98), and T cell rich B cell lymphoma (TCRBCL,3.1%, 3/98).
  • [MeSH-major] Biomarkers, Tumor / analysis. Gastrointestinal Neoplasms / pathology. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440591.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


96. Uccella S, Cerutti R, Placidi C, Marchet S, Carnevali I, Bernasconi B, Proserpio I, Pinotti G, Tibiletti MG, Furlan D, Capella C: MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. J Clin Pathol; 2009 Aug;62(8):715-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
  • AIMS:. (1) To validate a quantitative real time methylation specific PCR assay (MethyLight) for the detection of O6-methylguanine-DNA methyltransferase (MGMT) gene methylation status (MS) in diffuse large B-cell lymphoma (DLBCL). (2) To determine the immunohistochemical (IHC) expression of the MGMT protein and correlate it with MS.
  • Statistical analysis of overall survival (OS), lymphoma-specific survival (LSS) and progression free survival (PFS) was performed according to IHC and MS results.
  • [MeSH-major] Biomarkers, Tumor / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638543.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


97. Sun XF, Zhen ZJ, Xia Y, Yang QY, Wang ZH, Ling JY: [The clinical features of B cell lymphoblastic lymphoma and outcomes after BFM-90 regimen therapy]. Zhonghua Xue Ye Xue Za Zhi; 2006 Oct;27(10):649-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical features of B cell lymphoblastic lymphoma and outcomes after BFM-90 regimen therapy].
  • OBJECTIVE: To analyse the clinical features of patients with B cell lymphoblastic lymphoma(BCLL) and the outcomes after modified BFM-90 protocol therapy.
  • METHODS: The clinical features of 14 patients with BCLL were analysed, and compared with that of T cell lymphoblastic lymphoma in the same period.
  • RESULTS: The 14 patients were aged 3 to 18 and diagnosed as BCLL by morphology and immunohistology.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343193.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


98. López-Guillermo A, Colomo L, Jiménez M, Bosch F, Villamor N, Arenillas L, Muntañola A, Montoto S, Giné E, Colomer D, Beà S, Campo E, Montserrat E: Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol; 2005 Apr 20;23(12):2797-804
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
  • PURPOSE: To study the main clinicobiologic features, response, and outcome of patients with diffuse large B-cell lymphoma (DLBCL) according to the primary site, lymph node, or different extranodal organs of the disease.
  • Morphology, immunophenotyping, proliferation index, differentiation profile, bcl-2/JH rearrangement, and clinical characteristics were analyzed according to the primary site of the lymphoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymph Nodes / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Staging

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15728226.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Oscier D, Owen R, Johnson S: Splenic marginal zone lymphoma. Blood Rev; 2005 Jan;19(1):39-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic marginal zone lymphoma.
  • Splenic marginal zone lymphoma (SMZL) is an indolent B cell malignancy usually involving spleen, bone marrow and blood.
  • Diagnosis is based on a combination of lymphocyte morphology, immunophenotype and marrow and /or splenic histology.
  • There is no genetic abnormality specific for SMZL, but deletions of chromosome 7q are the commonest abnormality and are found in 30-50% of cases.
  • The median survival is 10-13 years and most disease-related deaths are associated with transformation to diffuse large cell lymphoma.
  • [MeSH-minor] DNA Mutational Analysis. Gene Expression Profiling. Humans. Immunophenotyping. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / therapy. Mutation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15572216.001).
  • [ISSN] 0268-960X
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 80
  •  go-up   go-down


100. Dunphy CH, O'Malley DP, Cheng L, Fodrie TY, Perkins SL, Kaiser-Rogers K: Primary mediastinal B-cell lymphoma: detection of BCL2 gene rearrangements by PCR analysis and FISH. J Hematop; 2008 Sep;1(2):77-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal B-cell lymphoma: detection of BCL2 gene rearrangements by PCR analysis and FISH.
  • Primary mediastinal large B-cell lymphoma (PMBCL) has a characteristic clinical presentation, morphology, and immunophenotype, representing a clinically favorable subgroup of diffuse large B-cell lymphoma (DLBCL).
  • By gene expression profiling (GEP), PMBCL shares features with classical Hodgkin lymphoma (cHL).
  • Of further interest, BCL6 gene mutations and BCL6 and/or MUM1 expression in a number of PMBCLs have supported an activated B-cell (ABC) origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1999 Oct;107(1):106-13 [10520030.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1172-80 [12429796.001]
  • [Cites] Histopathology. 1986 Apr;10(4):379-90 [2423430.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):748-56 [6784911.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S21-6 [15202521.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Feb;33(2):114-22 [11793437.001]
  • [Cites] Leuk Lymphoma. 2001 Mar;41(1-2):47-53 [11342356.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jun;31(2):191-5 [11319807.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Blood. 2000 Jan 15;95(2):651-9 [10627476.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):243-53 [12507907.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):2017-25 [8669486.001]
  • (PMID = 19669206.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2713480
  •  go-up   go-down






Advertisement